

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pr FREYA 21 and Pr FREYA 28

Desogestrel and Ethinyl estradiol Tablets

Tablets, 0.15 mg Desogestrel and 0.03 mg Ethinyl estradiol, Oral

USP

Oral Contraceptive

Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, Ontario
M8Z 2S6

Date of Initial Authorization:
NOV 09, 2012

Date of Revision:
AUG 01, 2023

Submission Control Number: 272650

RECENT MAJOR LABEL CHANGES

2 CONTRAINDICATIONS	08/2023
7 WARNINGS AND PRECAUTIONS, Hepatitis C	08/2023
7 WARNINGS AND PRECAUTIONS, Immune	08/2023

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics.....	4
1.2 Geriatrics.....	4
2 CONTRAINDICATIONS	4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX	5
4 DOSAGE AND ADMINISTRATION	5
4.1 Dosing Considerations	5
4.2 Recommended Dose and Dosage Adjustment	6
4.4 Administration	6
4.5 Missed Dose	7
5 OVERDOSAGE	9
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	9
7 WARNINGS AND PRECAUTIONS	10
7.1 Special Populations.....	18
7.1.1 Pregnant Women.....	18
7.1.2 Breast-feeding.....	18
7.1.3 Pediatrics.....	18
7.1.4 Geriatrics.....	18
8 ADVERSE REACTIONS	19
8.1 Adverse Reaction Overview	19
8.2 Clinical Trial Adverse Reactions	21

8.5	Post-Market Adverse Reactions.....	23
9	DRUG INTERACTIONS	24
9.2	Drug Interactions Overview	24
9.4	Drug-Drug Interactions	24
9.5	Drug-Food Interactions.....	30
9.6	Drug-Herb Interactions	30
9.7	Drug-Laboratory Test Interactions.....	30
10	CLINICAL PHARMACOLOGY	31
10.1	Mechanism of Action	31
10.2	Pharmacodynamics.....	31
10.3	Pharmacokinetics.....	32
11	STORAGE, STABILITY AND DISPOSAL.....	34
12	SPECIAL HANDLING INSTRUCTIONS.....	34
PART II: SCIENTIFIC INFORMATION		35
13	PHARMACEUTICAL INFORMATION	35
14	CLINICAL TRIALS	36
14.1	Clinical Trials by Indication	36
14.2	Comparative Bioavailability Studies	41
15	MICROBIOLOGY	42
16	NON-CLINICAL TOXICOLOGY	42
17	SUPPORTING PRODUCT MONOGRAPHS.....	49
PATIENT MEDICATION INFORMATION		50

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

FREYA (desogestrel/ethinyl estradiol tablets, USP) is indicated for:

- Conception control

1.1 Pediatrics

Pediatrics: The safety and efficacy of desogestrel/ethinyl estradiol tablets has not been established in women under the age of 18 years.

Use of this product before menarche is not indicated.

1.2 Geriatrics

Geriatrics: Desogestrel/ethinyl estradiol tablets are not indicated in postmenopausal women.

2 CONTRAINDICATIONS

Combined hormonal contraceptives (CHCs) should not be used in the presence of any of the conditions listed below. Should any of the conditions appear for the first time during CHC use, the product should be stopped immediately.

- Desogestrel/ethinyl estradiol tablets are contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#);
- presence or history of venous thrombosis (deep vein thrombosis, pulmonary embolism);
- a history of or actual cerebrovascular disorders;
- presence or history of arterial thrombosis (myocardial infarction, cerebrovascular accident) or prodromal conditions (eg, transient ischaemic attack, angina pectoris);
- valvular heart disease with complications;
- presence or history of severe hepatic disease as long as liver function values have not returned to normal;
- use with the Hepatitis C virus combination drug regimen ombitasvir/paritaprevir/ritonavir with or without dasabuvir or medicinal products containing glecaprevir/pibrentasvir (see [7 WARNINGS AND PRECAUTIONS](#) and [9 DRUG INTERACTIONS](#));
- presence or history of liver tumours (benign or malignant);
- known or suspected sex steroid-influenced malignancies (e.g., of the genital organs or of the breast);
- undiagnosed abnormal vaginal bleeding;

- steroid-dependant jaundice, cholestatic jaundice, history of jaundice of pregnancy;
- any ocular lesion arising from ophthalmic vascular disease, such as partial or complete loss of vision or defect in visual fields;
- known or suspected pregnancy;
- current or history of migraine with focal aura;
- history of or actual pancreatitis if associated with severe hypertriglyceridemia;
- presence of severe or multiple risk factor(s) for arterial or venous thrombosis:
 - severe hypertension (persistent values of $\geq 160/100$ mmHg)
 - hereditary or acquired predisposition for venous or arterial thrombosis, such as Factor V Leiden mutation and activated protein C(APC) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia (e.g., due to MTHFR C677T, A1298 mutations), prothrombin mutation G20210A, and antiphospholipid-antibodies (anticardiolipin antibodies, lupus anticoagulant)
 - severe dyslipoproteinemia
 - smoking and over age 35
 - diabetes mellitus with vascular involvement
 - major surgery associated with an increased risk of postoperative thromboembolism (see [7 WARNINGS AND PRECAUTIONS](#))
 - prolonged immobilization (see [7 WARNINGS AND PRECAUTIONS](#)).

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels. This risk increases with age and becomes significant in oral contraceptive users older than 35 years of age, and with the number of cigarettes smoked. For this reason, combination oral contraceptives, including FREYA, should not be used by women who are over 35 years of age and smoke (see [7 WARNINGS AND PRECAUTIONS](#)).

Patients should be counseled that birth control pills **DO NOT PROTECT** against sexually transmitted diseases (STDs) including HIV/AIDS. For protection against STDs, patients should be counseled to use latex condoms **IN COMBINATION WITH** birth control pills.

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

Patients should be instructed to read the package insert prior to starting FREYA and any time they are unsure of administration. In the case of FREYA 28, patients should be instructed to read the package insert and the day label strip. If they have additional questions, they should call their doctor or clinic.

FREYA tablets may be prescribed as a 21-day or a 28-day regimen. FREYA tablets must be taken at approximately the same time every day until the pack is empty. The patient may begin taking FREYA on Day 1 of her menstrual cycle (i.e., the first day of menstrual flow) or on the first Sunday after her period begins. If the patient's period starts on Sunday, she should start that same day.

4.2 Recommended Dose and Dosage Adjustment

FREYA 21 (21-Day Regimen): One white tablet is to be taken for 21 consecutive days (three weeks). Tablets are then discontinued for one week. The patient must not be off the pill for more than seven consecutive days. A new pack will be started on the eighth day. The patient will have a period during the seven days off the pill (bleeding may be lighter and shorter than their usual period.)

FREYA 28 (28-Day Regimen): One white tablet is to be taken for 21 consecutive days (three weeks), followed by a green tablet for seven consecutive days (one week). A new pack (white tablet) will be started on the eighth day, following the completion of the green tablets. The patient will have a period while they are on the green tablet. On this regimen the patient must not go a day without taking a pill.

4.4 Administration

It is recommended that FREYA be taken at the same time each day. The patient should be counselled to associate taking the pill with some regular activity like eating a meal or going to bed.

The first-time user may wish to use a second method of birth control (e.g., latex condoms and spermicidal foam or gel) for the first seven days of the first cycle of pill use. This will provide a back-up in case pills are forgotten while they are getting used to taking them.

If spotting, light bleeding, or feeling sick to their stomach occurs during the first three months the women should be counselled to not stop taking the pill. The problem will usually go away. If it does not subside, the patient should consult her doctor or clinic.

The dosage regimen should not be altered (i.e., the pill should not be stopped) even if the women does not have sex very often.

When receiving any medical treatment, patients should tell their doctor that they are using birth control pills.

Advice in case of vomiting

In case of severe gastro-intestinal disturbance, absorption may not be complete and additional contraceptive measures should be taken. If vomiting occurs within 3-4 hours after tablet-

taking, the advice concerning the Management of missed tablets is outlined below. If the woman does not want to change her normal tablet-taking schedule, she has to take the extra tablet(s) needed from another pack.

When to start FREYA

No hormonal contraceptive use in the preceding cycle: Tablet taking should start on Day 1 of the woman's menstrual cycle or on the first Sunday after her period begins.

Switching from another combination hormonal contraceptive (combined oral contraceptive (COC), vaginal ring, or transdermal patch): The woman should start FREYA preferably on the day after the last active tablet of her previous COC, but at the latest, on the day following the usual tablet-free or inactive tablet of her previous COC. In case a vaginal ring or transdermal patch has been used, the woman should start using FREYA preferably on the day of removal, but at the latest when the next application would have been due.

Switching from a progestogen-only-method (mini-pill, injection, implant) or from a progestogen-releasing intrauterine system (IUS): The woman may switch from the mini-pill to FREYA on any day of her cycle. Patients using a progestogen injection should start FREYA on the day the next injection is due. Patients using an implant or an IUS should start FREYA on the day it is removed. In all cases, the woman should be advised to use an additional barrier method for the first 7 days of FREYA use.

Following complete first-trimester abortion: The woman may start using FREYA immediately. When doing so, she need not take additional contraceptive measures.

Following delivery or second-trimester abortion: Women should be advised to start FREYA on Day 21 to 28 after delivery or second trimester abortion, after consulting with their physician. When starting later, the woman should be advised to use an additional barrier method for the first seven days of tablet-taking. However, if intercourse has already occurred, pregnancy should be excluded before the actual start of use or the woman should be advised to wait for her first menstrual period prior to starting FREYA.

The increased risk of venous thromboembolism (VTE) during the postpartum period should be considered when restarting FREYA (see [7 WARNINGS AND PRECAUTIONS](#)).

For breastfeeding women, see [7 WARNINGS AND PRECAUTIONS – Breastfeeding](#).

4.5 Missed Dose

The patient should be instructed to use the following chart if she misses one or more of her birth control pills. She should be told to match the number of pills missed with the appropriate starting time for her dosing regimen.

Sunday Start	Day One Start
Miss One Pill	Miss One Pill
Take it as soon as you remember, and take the next pill at the usual time. This means that you might take 2 pills in one day.	Take it as soon as you remember, and take the next pill at the usual time. This means that you might take 2 pills in one day.
Miss Two Pills in a Row	Miss Two Pills in a Row
First Two Weeks 1. Take 2 pills the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. Use a back-up method of birth control if you have sex in the 7 days after you miss the pills.	First Two Weeks 1. Take 2 pills the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. Use a back-up method of birth control if you have sex in the 7 days after you miss the pills.
Third Week 1. Keep taking 1 pill a day until Sunday. 2. On Sunday, safely discard the rest of the pack and start a new pack that day. 3. Use a back-up method of birth control if you have sex in the 7 days after you miss the pills. 4. You may not have a period this month. If you miss two periods in a row, call your doctor or clinic.	Third Week 1. Safely dispose of the rest of the pill pack and start a new pack that same day. 2. Use a back-up method of birth control if you have sex in the 7 days after you miss the pills. 3. You may not have a period this month. If you miss two periods in a row, call your doctor or clinic.
Miss Three or More Pills in a Row	Miss Three or More Pills in a Row
Anytime in the Cycle 1. Keep taking 1 pill a day until Sunday. 2. On Sunday, safely discard the rest of the pack and start a new pack that day. 3. Use a back-up method of birth control if you have sex in the 7 days after you miss the pills. 4. You may not have a period this month. If you miss two periods in a row, call your doctor or clinic.	Anytime in the Cycle 1. Safely dispose of the rest of the pill pack and start a new pack that same day. 2. Use a back-up method of birth control if you have sex in the 7 days after you miss the pills. 3. You may not have a period this month. If you miss two periods in a row, call your doctor or clinic.

Missing pills can cause spotting or light bleeding, even if the missed pills are made up. The woman may also feel a little sick to her stomach on the days she takes two pills to make up for missed pills.

If a woman misses pills at any time, she could get pregnant. The greatest risks for pregnancy are starting a pack late or missing a pill(s) at the beginning or at the very end of the pack.

The patient should be counselled to always have another kind of birth control (such as latex condoms and spermicidal foam or gel) to use as a back-up in case they miss pills, and an extra, full pack of pills available.

If the patient forgets more than one pill, two months in a row, they should be instructed to talk to their doctor or clinic. The patient may require further counselling about ways to make pill-taking easier or about using another method of birth control.

NOTE to Patients on the 28-day regimen (FREYA 28): If the patient forgets any of the seven green pills (without hormones) in Week 4, she should be advised to safely dispose of the pills she missed and then keep taking one pill each day until the pack is empty. A back-up method of birth control is not needed.

5 OVERDOSAGE

Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females. There are no antidotes and further treatment should be symptomatic.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Oral	FREYA 21 and FREYA 28 White tablets / 0.15 mg desogestrel and 0.03 mg ethinyl estradiol	Anhydrous lactose, colloidal silicon dioxide, polyvinyl pyrrolidone, potato starch, stearic acid and vitamin E.
Oral	FREYA 28 Green tablets (Placebo)	FD&C Blue No. 1, ferric oxide yellow, lactose monohydrate, magnesium stearate and polacrillin potassium.

Packaging

FREYA 21: Push-through strips of 21 white tablets each. Tablets are round, biconvex and 5 mm in diameter. They are embossed with **407** on one side and plain on the other side. The push-

through strip is a polyvinylchloride (PVC) coated with PVdC film backed by aluminum foil with a heat-seal lacquer.

Each blister contains 21 tablets and is packed in a sealed aluminum tri-laminated pouch. Each pouch is packed in a printed carton (monocarton) along with the patient information leaflet. Six monocartons are packed in an outer carton.

FREYA 28: Push-through strips with 21 white and 7 green tablets. Tablets are round, biconvex and 5 mm in diameter. The white tablets are embossed with **407** on one side and plain on the other side. The green tablets are embossed with **472** on one side and plain on the other side. The push-through strip is a polyvinylchloride (PVC) coated with PVdC film backed by aluminum foil with a heat-seal lacquer.

Each blister contains 28 tablets and is packed in a sealed aluminum tri-laminated pouch. Each pouch is packed in a printed carton (monocarton) along with the patient information leaflet and a day label strip. Six monocartons are packed in an outer carton.

7 WARNINGS AND PRECAUTIONS

General

Discontinue Medication at the Earliest Manifestation of:

- A. **Thromboembolic and cardiovascular disorders**, such as thrombophlebitis, pulmonary embolism, cerebrovascular disorders, myocardial ischemia, mesenteric thrombosis, and retinal thrombosis.
- B. **Conditions which predispose to venous stasis and to vascular thrombosis** (eg, immobilization after accidents or confinement to bed during long-term illness). Other non-hormonal methods of contraception should be used until regular activities are resumed. For use of oral contraceptives when surgery is contemplated, see [Peri-Operative Considerations](#).
- C. **Visual defects - partial or complete.**
- D. **Papilledema or ophthalmic vascular lesions.**
- E. **Severe headache of unknown etiology or worsening of pre-existing migraine headache.**
- F. **Increase in epileptic seizures**

Throughout this section the general term combined hormonal contraceptives (CHC) is used when data exist for oral and non-oral contraceptives. The term combined oral contraceptives (COC) is used when data exist only for oral contraceptives.

The following information is provided from studies of combination oral contraceptives (COCs).

The use of COCs is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia and gallbladder disease,

although the risk of serious morbidity and mortality is small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly if associated with the presence of other risk factors such as hypertension, hyperlipidemias, obesity and diabetes. Other medical conditions which have been associated with adverse circulatory events include systemic lupus erythematosus, hemolytic uremic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis), sickle cell disease, valvular heart disease and atrial fibrillation.

The following conditions have been reported to occur or deteriorate with both pregnancy and COC use, although a direct association with COCs' has not been firmly established: jaundice and/or pruritus related to cholestasis; gallstone formation; porphyria, systemic lupus erythematosus, hemolytic uremic syndrome, Sydenham's chorea, herpes gestationis and otosclerosis-related hearing loss; (hereditary) angioedema.

The information contained in this section is principally from studies carried out in women who used COC with higher formulations of estrogen and progestogens than those in common use today. The effect of long-term use of COCs with lower doses of both estrogen and progestogen remains to be determined.

Carcinogenesis and Mutagenesis

Breast Cancer

Increasing age and a strong family history are the most significant risk factors for the development of breast cancer. Other established risk factors include obesity, nulliparity and late age for first full-term pregnancy. The identified groups of women that may be at increased risk of developing breast cancer before menopause are long-term users of oral contraceptives (more than eight years) and starters at early age. In a few women, the use of oral contraceptives may accelerate the growth of an existing but undiagnosed breast cancer. Since any potential increased risk related to oral contraceptive use is small, there is no reason to change prescribing habits at present.

Women receiving oral contraceptives should be instructed in self-examination of their breasts. Their physician should be notified whenever any masses are detected. A yearly clinical breast examination is also recommended, because, if a breast cancer should develop, drugs that contain estrogen may cause a rapid progression.

Cervical Cancer

The most important risk factor for cervical cancer is persistent human papilloma virus (HPV) infection. Some epidemiological studies have indicated that long-term use of COCs may further contribute to this increased risk but there continues to be controversy about the extent to which this finding is attributable to the confounding effects, e.g., cervical screening and sexual behavior including use of barrier contraceptives.

Hepatocellular Carcinoma

Hepatocellular carcinoma may be associated with oral contraceptives. The risk appears to increase with duration of hormonal contraceptive use. However, the attributable risk (the excess incidence) of liver cancers in oral contraceptive users is extremely small.

Cardiovascular

Predisposing Factors for Coronary Artery Disease

Cigarette smoking increases the risk of serious cardiovascular side effects and mortality. Birth control pills increase this risk, especially with increasing age. Convincing data are available to support an upper age limit of 35 years for oral contraceptive use in women who smoke.

Other women who are independently at high risk for cardiovascular disease include those with diabetes, hypertension, abnormal lipid profile or a family history of these. Whether oral contraceptives accentuate this risk is unclear.

In low risk, non-smoking women of any age, the benefits of oral contraceptive use outweigh the possible cardiovascular risks associated with low dose formulations. Consequently, oral contraceptives may be prescribed for these women up to the age of menopause.

Hypertension

Patients with essential hypertension whose blood pressure is well-controlled may be given hormonal contraceptives but only under close supervision. If a significant elevation of blood pressure in previously normotensive or hypertensive subjects occurs at any time during the administration of the drug, cessation of medication is necessary.

Endocrine and Metabolism

Diabetes

Current low dose oral contraceptives exert minimal impact on glucose metabolism. Diabetic patients, or those with a family history of diabetes, should be observed closely to detect any worsening of carbohydrate metabolism. Patients predisposed to diabetes who can be kept under close supervision may be given oral contraceptives. Young diabetic patients whose disease is of recent origin, well-controlled, and not associated with hypertension or other signs of vascular disease such as ocular fundal changes, should be monitored more frequently while using oral contraceptives.

Lipid and Other Metabolic Effects

A small proportion of women will have adverse lipid changes while on oral contraceptives. Alternative contraception should be used in women with uncontrolled dyslipidemias. (See also [2 CONTRAINDICATIONS](#)). Elevations of plasma triglycerides may lead to pancreatitis and other complications.

Gastrointestinal

Published epidemiological studies indicate a possible association of COC use and the development of Crohn's disease and ulcerative colitis, although this has not been firmly established.

Genitourinary

Vaginal Bleeding

Persistent irregular vaginal bleeding requires assessment to exclude underlying pathology.

Fibroids

Patients with fibroids (leiomyomata) should be carefully observed. Sudden enlargement, pain or tenderness requires discontinuation of the use of oral contraceptives.

Hematologic

Epidemiological studies have shown an association between the use of CHCs and an increased risk of arterial and venous thrombotic and thromboembolic diseases such as myocardial infarction, stroke, deep venous thrombosis, and pulmonary embolism.

Epidemiological studies have shown that the incidence of venous thromboembolism (VTE) in users of CHC with low estrogen content (<50 mcg ethinyl estradiol) ranges from about 3 to 12 cases per 10,000 women-years, but the risk estimate varies according to the progestogen. This compares with 1 to 5 cases per 10,000 women-years for non-CHC users.

The use of CHCs carries an increased risk of VTE compared with no use. The excess risk of VTE is highest during the first year a woman ever uses a CHC. The increased risk is less than the risk of VTE associated with pregnancy, which is estimated as 5 to 20 cases per 10,000 women-years or the risk in the postpartum period which is estimated as 40-65 cases per 10,000 women-years. The risk is also increased after initially starting a CHC or restarting the same or different CHC after a break in use of 4 weeks or more. VTE is fatal in 1-2% of cases.

Several epidemiological studies indicate that third generation oral contraceptives, including those containing desogestrel, are associated with a higher risk of venous thromboembolism than certain second generation oral contraceptives. These studies indicate an approximate 2-fold difference in risk, which corresponds to 1-2 cases of venous thromboembolism per 10,000 women-years of use. However, data from additional studies have not shown this difference in risk.

Extremely rarely, thrombosis has been reported to occur in other blood vessels, e.g., hepatic, mesenteric, renal, cerebral or retinal veins and arteries, in CHC users.

Symptoms of venous or arterial thrombotic/thromboembolic events or of a cerebrovascular

accident can include: unilateral leg pain and/ or swelling; sudden severe pain in the chest, whether or not it radiates to the left arm; sudden breathlessness; sudden onset of coughing; any unusual, severe, prolonged headache; sudden partial or complete loss of vision; diplopia; slurred speech or aphasia; vertigo; collapse with or without focal seizure; weakness or very marked numbness suddenly affecting one side or one part of the body; motor disturbances; 'acute' abdomen.

Other Risk Factors for Venous Thromboembolism

Other generalized risk factors for venous thromboembolism include but are not limited to:

- a personal history,
- a positive family history (the occurrence of VTE in a direct relative at a relatively early age). If a hereditary or acquired predisposition for venous thromboembolism is suspected, the woman should be referred to a specialist for advice before deciding on any CHC use.
- severe obesity (body mass index $>30\text{kg}/\text{m}^2$),
- systemic lupus erythematosus.

The risk of VTE also increases with increasing age and smoking.

The risk of VTE may be temporarily increased with prolonged immobilization, major surgery, any surgery to the legs or major trauma. In these situations, it is advisable to discontinue CHC use (in the case of elective surgery at least four weeks in advance) and not to resume until two weeks after complete remobilization (see [2 CONTRAINDICATIONS](#)).

Also, patients with superficial thrombophlebitis and varicose veins and leg cast should be closely supervised. There is no consensus about the possible role of these conditions in the etiology of venous thromboembolism.

Other Risk Factors for Arterial Thromboembolism

The risk of arterial thromboembolic complications increases with:

- increasing age;
- smoking (with heavier smoking and increasing age the risk further increases, especially in women over 35 years of age);
- dyslipoproteinemia;
- obesity (body mass index over $30\text{ kg}/\text{m}^2$);
- hypertension;
- migraine;
- valvular heart disease;
- atrial fibrillation;
- a positive family history (i.e. arterial thrombosis ever in a sibling or parent at a relatively early age). If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any hormonal contraceptive use.

Hepatic/Biliary/Pancreatic

Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal.

Jaundice

Patients who have had jaundice should be given oral contraceptives only with great care and under close observation. Oral contraceptive-related cholestasis has been described in women with a history of pregnancy-related cholestasis. Women with a history of cholestasis may have the condition recur with subsequent hormonal contraceptive use.

The development of severe generalized pruritus or icterus requires that the medication be withdrawn until the problem is resolved.

If a patient develops jaundice that proves to be cholestatic in type, the use of oral contraceptives should not be resumed. In patients taking hormonal contraceptives, changes in the composition of the bile may occur and an increased incidence of gallstones has been reported.

Gallbladder Disease

Patients taking oral contraceptives have a greater risk of developing gallbladder disease requiring surgery within the first year of use. The risk may double after four or five years.

Hepatic Nodules

Hepatic nodules (adenoma and focal nodular hyperplasia) have been reported, particularly in long-term users of oral contraceptives. Although these lesions are extremely rare, they have caused fatal intra-abdominal hemorrhage and should be considered in women presenting with an abdominal mass, acute abdominal pain, or evidence of intra-abdominal bleeding.

Hepatitis C

During clinical trials with some HCV combination drug regimens, ALT elevations were observed in women using ethinylestradiol containing medications. For example, the HCV combination drug regimen ombitasvir/paritaprevir/ritonavir with and without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN) were significantly more frequent in women using ethinylestradiol-containing medications such as CHCs. Additionally, in patients treated with glecaprevir/pibrentasvir, ALT elevations were observed in women using ethinylestradiol-containing medications such as CHCs. FREYA must be discontinued prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir with or without dasabuvir or medicinal products containing glecaprevir/pibrentasvir. (see [2 CONTRAINDICATIONS](#) and [9 DRUG INTERACTIONS](#)). FREYA can be restarted approximately 2 weeks following completion of treatment with the HCV combination drug regimen.

Immune

Angioedema

Exogenous estrogens may induce or exacerbate symptoms of hereditary and acquired angioedema.

Monitoring and Laboratory Tests

Physical Examination and Follow-up

Before oral contraceptives are used, a thorough history and physical examination should be performed, including a blood pressure determination and the family case history carefully noted. In addition, disturbances of the clotting system must be ruled out if any members of the family have suffered from thromboembolic diseases (e.g., deep vein thrombosis, stroke, myocardial infarction) at a young age. Breasts, liver, extremities and pelvic organs should be examined and a Papanicolaou (PAP) smear should be taken if the patient has been sexually active.

The first follow-up visit should be done three months after oral contraceptives are prescribed. Thereafter, examinations should be performed at least once a year or more frequently if indicated. At each annual visit, examination should include those procedures that were done at the initial visit as outlined above or per recommendations of the Canadian Task Force on the Periodic Health Examination.

Neurologic

Migraine and Headache

The onset or exacerbation of migraine or the development of headaches with a new pattern that is recurrent, persistent or severe, requires discontinuation of hormonal contraceptives and evaluation of the cause. Women with migraine headaches who take oral contraceptives may be at increased risk of stroke (see [2 CONTRAINDICATIONS](#)).

Ophthalmologic

Patients who are pregnant or are taking oral contraceptives may experience corneal edema that may cause visual disturbances and changes in tolerance to contact lenses, especially of the rigid type. Soft contact lenses usually do not cause disturbances. If visual changes or alterations in tolerance to contact lenses occur, temporary or permanent cessation of wear may be advised.

Peri-Operative Considerations

There is an increased risk of thromboembolic complications in oral contraceptive users after major surgery. If feasible, oral contraceptives should be discontinued and an alternative method substituted at least one month prior to **MAJOR** elective surgery. Oral contraceptive

use should not be resumed until the first menstrual period after hospital discharge following surgery.

Psychiatric

Patients with a history of emotional disturbances, especially the depressive type, may be more prone to have a recurrence of depression while taking oral contraceptives. In cases of a serious recurrence, a trial of an alternate method of contraception should be made, which may help to clarify the possible relationship. Women with premenstrual syndrome (PMS) may have a varied response to oral contraceptives, ranging from symptomatic improvement to worsening of the condition.

Renal

Fluid Retention

Hormonal contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring in patients with conditions which might be aggravated by fluid retention.

Reproductive Health: Female Potential

Fertility

After discontinuing oral contraceptive therapy, the patient should delay pregnancy until at least one normal spontaneous menstrual cycle has occurred in order to date the pregnancy. An alternate contraceptive method should be used during this time.

Amenorrhea

In some women, withdrawal bleeding may not occur during the tablet-free interval. If the COC has been taken according to directions, it is unlikely that the woman is pregnant. However, if the COC has not been taken according to directions prior to the first missed withdrawal bleed, or if two withdrawal bleeds are missed, pregnancy must be ruled out before COC use is continued.

Women having a history of oligomenorrhea, secondary amenorrhea, or irregular cycles may remain anovulatory or become amenorrheic following discontinuation of estrogen-progestin combination therapy.

Amenorrhea, especially if associated with breast secretion, which continues for six months or more after withdrawal, warrants a careful assessment of hypothalamic-pituitary function.

Reduced Efficacy

The efficacy of FREYA may be reduced in the event of missed tablets, gastro-intestinal disturbances or concomitant medications that decrease the plasma concentration of ethinyl estradiol and/or etonogestrel, the active metabolite of desogestrel (see [9 DRUG](#))

INTERACTIONS).

Skin

Chloasma may occasionally occur with use of COCs, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking COCs.

7.1 Special Populations

7.1.1 Pregnant Women

Oral contraceptives should not be taken by pregnant women. If pregnancy occurs during treatment with FREYA, further intake should be stopped. However, if conception accidentally occurs while taking the pill, there is no conclusive evidence that the estrogen and progestin contained in the oral contraceptive will damage the developing child.

7.1.2 Breast-feeding

In breast-feeding women, the use of oral contraceptives results in the hormonal components being excreted in breast milk and may reduce its quantity and quality. Published studies have indicated that during lactation, 0.1% of the daily maternal dose of levonorgestrel and 0.02% of the daily maternal dose of ethinyl estradiol could be transferred to the newborn via milk. Adverse effects on the child have been reported, including jaundice and breast enlargement. The nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child.

7.1.3 Pediatrics

The safety and efficacy of desogestrel and ethinyl estradiol tablets has not been established in women under the age of 18 years.

Use of this product before menarche is not indicated.

7.1.4 Geriatrics

FREYA is not indicated in postmenopausal women.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

An increased risk of the following serious adverse reactions has been associated with the use of combination hormonal contraceptives:

- arterial and venous thromboembolism
- benign and malignant hepatic tumours
- cerebral hemorrhage
- cerebral thrombosis
- congenital anomalies
- gallbladder disease
- hypertension
- mesenteric thrombosis
- myocardial infarction
- neuro-ocular lesions (e.g., retinal thrombosis)
- pulmonary embolism
- thrombophlebitis

The following other adverse reactions also have been reported in patients receiving combination hormonal contraceptives: nausea and vomiting, usually the most common adverse reaction, occurs in approximately 10% or fewer of patients during the first cycle. The following other reactions, as a general rule, are seen less frequently or only occasionally:

- abdominal pain
- amenorrhea during and after treatment
- angioedema (exogenous estrogens may induce or exacerbate symptoms of angioedema in women with hereditary and acquired angioedema)^a
- auditory disturbances
- breakthrough bleeding
- breast changes (tenderness, enlargement, and secretion)
- cataracts
- changes in appetite
- change in corneal curvature (steepening)
- changes in glucose tolerance or effect on peripheral insulin resistance
- changes in libido
- change in menstrual flow
- change in weight (increase or decrease)
- chloasma or melasma which may persist
- cholestatic jaundice
- chorea
- Crohn's disease

- cystitis-like syndrome
- diarrhea
- dizziness
- dysmenorrhea
- edema
- endocervical hyperplasia
- erythema multiforme
- erythema nodosum
- gallstone formation^a
- gastrointestinal symptoms (such as abdominal cramps and bloating)
- headache
- hemolytic uremic syndrome
- hemorrhagic eruption
- herpes gestationis^a
- hirsutism
- hypersensitivity
- hypertension^a
- hypertriglyceridemia (increased risk of pancreatitis when using COCs)
- impaired renal function
- increase in size of uterine leiomyomata
- intolerance to contact lenses
- jaundice related to cholestasis^a
- liver function disturbances
- loss of scalp hair
- mental depression
- migraine
- nervousness
- optic neuritis
- otosclerosis-related hearing loss^a
- pancreatitis
- porphyria
- possible diminution in lactation when given immediately postpartum
- premenstrual-like syndrome
- pruritus related to cholestasis^a
- rash (allergic)
- Raynaud's phenomenon
- reduced tolerance to carbohydrates
- retinal thrombosis
- rhinitis
- spotting
- Sydenham's chorea^a
- Systemic lupus erythematosus^a

- temporary infertility after discontinuation of treatment
- ulcerative colitis
- urticaria
- vaginal candidiasis
- vaginal discharge
- vaginitis

^a Occurrence or deterioration of conditions for which association with COC use is not conclusive.

8.2 Clinical Trial Adverse Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Eighty-six per cent of the 1,195 subjects reported 1 or more adverse experiences. The majority of these (64%) were considered (by the investigators) to be unrelated to desogestrel and ethinyl estradiol tablets usage. Of the total population, approximately 12% of the subjects discontinued due to an adverse experience.

Table 2 – OVERALL ASSESSMENT OF CLINICAL ADVERSE EXPERIENCES (AES) ALL-PATIENTS-TREATED-GROUP

CLINICAL AE CATEGORIES	STARTERS		SWITCHERS		TOTAL	
	N	(%) ^a	N	(%)	N (%)	
Total Patients Entered	549	(100.0)	645	(100.0)	1,194 ^b	(100.0)
Patients with a Clinical AE	458	(83.4)	569	(88.2)	1,027	(86.0)
Patients with a Serious Clinical AE	20	(3.6)	18	(2.7)	38	(3.1)
Patients with Clinical AEs Contributing to Discontinuation ^c	76	(13.8)	70	(10.9)	146	(12.2)
Patients with a Reasonably Possibly, Probably or Definitely Drug-Related Clinical AE	197	(35.8)	236	(36.5)	433	(36.2)

^a Percentages are of total patients entered.

^b Starter/Switcher status could not be determined in one subject.

^c A total of 145 patients actually had a clinical AE as the primary reason for discontinuation.

With the exception of menses-related adverse experiences, no significant changes in the incidence of adverse experiences over time were seen. No drug-related adverse effects were

observed during general physical or pelvic examination. The breast examination showed a reduction in nodularity. No changes in body mass index or blood pressure were observed. Baseline distribution of abnormalities in cervical cytology was comparable to those at last visit. No patient developed a clinically significant abnormal value for routine laboratory analytes that led to either early discontinuation or hospitalization.

Detailed ophthalmologic examinations, including slit-lamp, were performed in a subset of 28 healthy women at baseline and after 12 cycles. No patients were found to have a decrease in visual acuity. Complete ophthalmological examination failed to identify possible desogestrel and ethinyl estradiol tablets-related changes.

Table 3 – PREVALENCE OF MOST FREQUENT^a SIDE EFFECTS OVER CYCLES INCIDENCE DURING STUDY WITH N=1,195 TOTAL (PER CENT)

– Body System –	Cycle Number						
	1	2	3		12	18	21
	Number of Patients Per Cycle						
Adverse Experience	1,095	1,064	1,001	863	465	115	30
– Body as a Whole –							
Abdominal Pain	115 (10.5)	71 (6.7)	58 (5.8)	42 (4.9)	20 (4.3)	4 (3.5)	1 (3.3)
Asthenia	27 (2.5)	18 (1.7)	11 (1.1)	11 (1.3)	2 (0.4)	1 (0.9)	1 (3.3)
Malaise	26 (2.4)	13 (1.2)	10 (1.0)	6 (0.7)	4 (0.9)	2 (1.7)	0 (0.0)
– Digestive –							
Diarrhea	40 (3.6)	29 (2.7)	23 (2.3)	26 (3.0)	3 (0.6)	2 (1.7)	0 (0.0)
Dyspepsia	13 (1.2)	12 (1.1)	9 (0.9)	10 (1.2)	5 (1.1)	0 (0.0)	0 (0.0)
Nausea	99 (9.0)	66 (6.2)	55 (5.5)	26 (3.0)	8 (1.7)	3 (2.6)	0 (0.0)
Vomiting	25 (2.3)	22 (2.1)	21 (2.1)	16 (1.8)	4 (0.9)	0 (0.0)	1 (3.3)
– Musculoskeletal –							
Back Pain	78 (7.1)	47 (4.4)	30 (3.0)	27 (3.1)	14 (3.0)	3 (2.6)	1 (3.3)
– Nervous System / Psychiatric –							
Depression	25 (2.3)	20 (1.9)	18 (1.8)	10 (1.2)	4 (0.9)	1 (0.9)	0 (0.0)
Dizziness	18 (1.6)	16 (1.5)	8 (0.8)	18 (2.1)	3 (0.6)	1 (0.9)	0 (0.0)
Headache	389 (35.5)	286 (26.9)	220 (22.0)	191 (22.1)	87 (18.7)	19 (16.5)	5 (16.7)
Migraine	21 (1.9)	23 (2.2)	13 (1.3)	11 (1.3)	3 (0.6)	0 (0.0)	0 (0.0)
– Respiratory –							
Allergic Rhinitis	9 (0.8)	11 (1.0)	13 (1.3)	9 (1.0)	12 (2.6)	1 (0.9)	0 (0.0)
Cough	26 (2.4)	17 (1.6)	17 (1.7)	16 (1.8)	5 (1.1)	2 (1.7)	0 (0.0)
Influenza	25 (2.3)	27 (2.5)	11 (1.1)	11 (1.3)	4 (0.9)	1 (0.9)	0 (0.0)
Pharyngitis	65 (5.9)	45 (4.2)	42 (4.2)	27 (3.1)	11 (2.4)	5 (4.4)	0 (0.0)
Upper Respiratory	93 (8.5)	86 (8.1)	63 (6.3)	52 (6.0)	20 (4.3)	7 (6.1)	1 (3.3)

– Body System –	Cycle Number						
	1	2	3		12	18	21
Adverse Experience	Number of Patients Per Cycle						
	1,095	1,064	1,001	863	465	115	30
Infection							
– Urogenital –							
Breast Pain	75 (6.8)	55 (5.2)	51 (5.1)	15 (1.7)	4 (0.9)	1 (0.9)	0 (0.0)
Dysmenorrhea	323 (29.5)	155 (14.6)	121 (12.1)	88 (10.2)	49 (10.5)	8 (7.0)	5 (16.7)
Vaginal Candidiasis	11 (1.0)	12 (1.1)	7 (0.7)	14 (1.6)	9 (1.9)	3 (2.6)	0 (0.0)
Cystitis	9 (0.8)	11 (1.0)	7 (0.7)	5 (0.6)	4 (0.9)	1 (0.9)	0 (0.0)

^a Adverse experiences reported by >5% of patients.

8.5 Post-Market Adverse Reactions

The most serious undesirable effects associated with the use of COCs are listed in WARNINGS AND PRECAUTIONS. Other side effects that have been reported in users of COCs but for which the association has been neither confirmed nor refuted are:¹

Table 4 – Side effects reported in users of COCs but for which the association has been neither confirmed nor refuted

Body system	Common/Uncommon (more than 1/1000)	Rare (less than 1/1000)
Immune system disorders		Hypersensitivity
Metabolism and nutrition disorders	Weight increased, fluid retention	Weight decreased
Nervous system disorders	Headache, migraine, libido decreased, depressed mood, mood altered	Libido increased
Eye disorders		Contact lens intolerance
Gastrointestinal disorders	Nausea, vomiting, abdominal pain, diarrhea	
Skin and subcutaneous tissue disorders	Rash, urticaria	Erythema nodosum, erythema multiforme
Reproductive system and breast disorders	Breast pain, breast tenderness, breast hypertrophy	Vaginal discharge, breast discharge

¹ The most appropriate MedDRA term (version 6.1) to describe a certain adverse reaction is listed. Synonyms or related conditions are not listed, but should be taken into account as well.

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

Note: The prescribing information of concomitant medications should be consulted to identify potential interactions.

The concurrent administration of oral contraceptives with other medicinal products may lead to breakthrough bleeding and/or may result in an altered response to either agent (see table 1 and 2). Reduced effectiveness of the oral contraceptive, should it occur, is more likely with the low dose formulations. It is important to ascertain all drugs that a patient is taking, both prescription and non-prescription, before oral contraceptives are prescribed.

Hepatic metabolism: Interactions can occur with medicinal or herbal products that induce microsomal enzymes, specifically cytochrome P450 enzymes (CYP), which can result in increased clearance reducing plasma concentrations of sex hormones and may decrease the effectiveness of combined oral contraceptives, including desogestrel and ethinyl estradiol tablets. These products are identified in [Drug-Drug Interactions](#) and [Drug-Herb Interactions](#) with an (*). Enzyme induction can occur after a few days of treatment. Maximum enzyme induction is generally observed within a few weeks. After drug therapy is discontinued, enzyme induction can last for about 28 days.

For women on long-term therapy with enzyme-inducing medicinal products, an alternative method of contraception unaffected by enzyme-inducing medicinal products should be considered.

9.4 Drug-Drug Interactions

Table 5 – Drugs Which May Decrease the Efficacy of Oral Contraceptives

Class of Compound	Drug	Proposed Mechanism	Suggested Management
Antacids		Decreased intestinal absorption of progestins.	Dose two hours apart.
Antibiotics	Rifabutin(*) Rifampicin(*)	Increased metabolism of progestins. Suspected acceleration of estrogen metabolism.	Use another method. For short course, use a barrier contraceptive method in addition to FREYA during administration and for 28 days after discontinuation of the enzyme inducing drug. For long course of enzyme inducing drugs, use

Class of Compound	Drug	Proposed Mechanism	Suggested Management
			another method of contraception unaffected by enzyme induction.
	Chloramphenicol Neomycin Nitrofurantoin Sulfonamides	Induction of hepatic microsomal enzymes. Also, disturbance of enterohepatic circulation.	For short course, use a barrier contraceptive method in addition to FREYA during administration and for 28 days after discontinuation of the enzyme inducing drug. For long course of enzyme inducing drugs, use another method of contraception unaffected by enzyme induction.
	Troleandomycin	May retard metabolism of oral contraceptives, increasing the risk of cholestatic jaundice.	
Anticonvulsants	Carbamazepine(*) Felbamate(*) Lamotrigine Oxcarbazepine(*) Phenobarbital Phenytoin(*) Primidone(*) Topiramate(*)	Induction of hepatic microsomal enzymes. Rapid metabolism of estrogen and increased binding of progestin and ethinyl estradiol to SHBG.	For short course, use a barrier contraceptive method in addition to FREYA during administration and for 28 days after discontinuation of the enzyme inducing drug. For long course of enzyme inducing drugs, use another method of contraception unaffected by enzyme induction.
Antifungals	Griseofulvin(*)	Stimulation of hepatic metabolism of contraceptive steroids may occur.	Use another method. For short course, use a barrier contraceptive method in addition to FREYA during administration and for 28 days after discontinuation of the enzyme inducing drug. For long course of enzyme inducing drugs, use another method of contraception unaffected by enzyme induction.

Class of Compound	Drug	Proposed Mechanism	Suggested Management
Cholesterol Lowering Agents	Clofibrate	Reduces elevated serum triglycerides and cholesterol; this reduces oral contraceptive efficacy.	Use another method.
HCV protease inhibitors HIV protease inhibitors Non-nucleoside reverse transcriptase inhibitors	Boceprevir Telaprevir Nelfinavir(*) Ritonavir(*) Nevirapine Efavirenz(*)	HCV and HIV combination therapy may alter clearance of the sex hormones; decreased, increased or no change in the plasma concentrations of the progestin or estrogen component.	For short course, use a barrier contraceptive method in addition to FREYA during administration and for 28 days after discontinuation of the enzyme inducing drug. For long course of enzyme inducing drugs, use another method of contraception unaffected by enzyme induction.
Sedatives and Hypnotics	Barbiturates Glutethimide(*) Meprobamate(*)	Induction of hepatic microsomal enzymes.	For short course, use a barrier contraceptive method in addition to FREYA during administration and for 28 days after discontinuation of the enzyme inducing drug. For long course of enzyme inducing drugs, use another method of contraception unaffected by enzyme induction.
Pulmonary arterial hypertension Drugs	Bosentan(*)	Induction of hepatic microsomal enzymes.	For short course, use a barrier contraceptive method in addition to FREYA during administration and for 28 days after discontinuation of the enzyme inducing drug. For long course of enzyme inducing drugs, use another method of contraception unaffected by enzyme induction.

Class of Compound	Drug	Proposed Mechanism	Suggested Management
Other Drugs	Analgesics Antihistamines Antimigraine preparations Phenylbutazone Vitamin E	Reduced oral contraceptive efficacy has been reported. Remains to be confirmed.	

Oral contraceptives may interfere with the metabolism of other drugs. Accordingly, plasma and tissue may either increase (e.g., cyclosporine) or decrease (e.g. lamotrigine).

If concomitant drug administration runs beyond the end of the tablets in the current COC pack, the next COC pack should be started right away without the usual tablet-free interval.

Table 6 – Modification of Other Drug Action by Oral Contraceptives

Class of Compound	Drug	Modification of Drug Action	Suggested Management
Alcohol		Possible increased levels of ethanol or acetaldehyde.	Use with caution.
Alpha-II adrenoreceptor agents	Clonidine	Sedation effect increased.	Use with caution.
Anticoagulants	All	Oral contraceptives increase clotting factors, decrease efficacy. However oral contraceptives may potentiate action in some patients.	Use another method.
Anticonvulsants	All	Estrogens may increase risk of seizures.	Use another method.
	Lamotrigine	Decreased lamotrigine levels, may lead to breakthrough seizures.	Use another method.
Antidiabetic drugs	Oral hypoglycemics and insulin	Oral contraceptives may impair glucose tolerance and increase blood glucose.	Use low dose estrogen and progestin oral contraceptive or another method. Monitor blood glucose.

Class of Compound	Drug	Modification of Drug Action	Suggested Management
Antihypertensive agents	Guanethidine and methyldopa	Estrogen component causes sodium retention, progestin has no effect.	Use low estrogen oral contraceptive or use another method.
	Beta blockers	Increased drug effect (decreased metabolism).	Adjust dose of drug if necessary. Monitor cardiovascular status.
Antipyretics	Acetaminophen	Increased metabolism and renal clearance.	Dose of drug may have to be increased.
	Antipyridine	Impaired metabolism.	Decrease dose of drug.
	ASA	Effects of ASA may be decreased by the short-term use of oral contraceptives.	Patients on chronic ASA therapy may require an increase in ASA dosage.
Aminocaproic acid		Theoretically, a hypercoagulable state may occur because oral contraceptives augment clotting factors.	Avoid concomitant use.
Betamimetic agents	Isoproterenol	Estrogen causes decreased response to these drugs.	Adjust dose of drug as necessary. Discontinuing oral contraceptives can result in excessive drug activity.
Caffeine		The actions of caffeine may be enhanced as oral contraceptives may impair the hepatic metabolism of caffeine.	Use with caution.
Cholesterol lowering agents	Clofibrate	Their action may be antagonized by oral contraceptives. Oral contraceptives may also increase metabolism of clofibrate.	May need to increase dose of clofibrate.
Corticosteroids	Prednisone	Markedly increased serum levels.	Possible need for decrease in dose.
Cyclosporine		May lead to an increase in cyclosporine levels and hepatotoxicity.	Monitor hepatic function. The cyclosporine dose may have to be decreased.

Class of Compound	Drug	Modification of Drug Action	Suggested Management
Folic acid		Oral contraceptives have been reported to impair folate metabolism.	May need to increase dietary intake, or supplement.
Meperidine		Possible increased analgesia and CNS depression due to decreased metabolism of meperidine.	Use combination with caution.
Phenothiazine tranquilizers	All phenothiazines, reserpine and similar drugs.	Estrogen potentiates the hyperprolactinemia effect of these drugs.	Use other drugs or lower dose oral contraceptives. If galactorrhea or hyperprolactinemia, occurs use other method.
Sedatives and hypnotics	Chlordiazepoxide Lorazepam Oxazepam Diazepam	Increased effect (increased metabolism)	Use with caution
Theophylline	All	Decreased oxidation, leading to possible toxicity.	Use with caution. Monitor theophylline levels.
Tricyclic antidepressants	Clomipramine (possibly others)	Increased side effects; i.e. depression.	Use with caution
Vitamin B ₁₂		Oral contraceptives have been reported to reduce serum levels of Vitamin B ₁₂ .	May need to increase dietary intake, or supplement.

When co-administered with hormonal contraceptives, many combinations of HIV protease inhibitors (e.g., nelfinavir) and non-nucleoside reverse transcriptase inhibitors (e.g., nevirapine), and/or combinations with Hepatitis C virus (HCV) medicinal products (e.g., boceprevir, telaprevir) can increase or decrease plasma concentrations of progestins, including etonogestrel, the active metabolite of desogestrel, or estrogens. The net effect of these changes may be clinically relevant in some cases.

During clinical trials with the HCV combination drug regimen ombitasvir /paritaprevir/ritonavir with and without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN) were significantly more frequent in women using ethinylestradiol-containing medications such as CHCs. FREYA must be discontinued prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir with or without dasabuvir (see [2 CONTRAINDICATIONS](#) and [7 WARNINGS AND PRECAUTIONS](#)). FREYA can be restarted

approximately 2 weeks following completion of treatment with the HCV combination drug regimen. Concomitant use with some other HCV antiviral medicinal products, such as those containing glecaprevir/pibrentasvir, may also increase the risk of ALT elevations.

Concomitant administration of strong (e.g., ketoconazole, itraconazole, clarithromycin) or moderate (e.g., fluconazole, diltiazem, erythromycin) CYP 3A4 inhibitors may increase the serum concentrations of estrogens or progestins, including etonogestrel, the active metabolite of desogestrel.

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Herbal products containing St. John's Wort(*) (*hypericum perforatum*) may induce hepatic enzymes (cytochrome P450) and p-glycoprotein transporter and may reduce the effectiveness of contraceptive steroids. This may also result in breakthrough bleeding. For short course, a barrier contraceptive method should be used in addition to FREYA during administration and for 28 days after discontinuation of the herbal product. For long course, use another method of contraception.

9.7 Drug-Laboratory Test Interactions

Results of laboratory tests should be interpreted with the knowledge that the patient is taking an oral contraceptive. The following laboratory tests are modified.

Liver Function Tests

Aspartate serum transaminase (AST) - variously reported elevations

Alkaline phosphatase and gamma glutamine transaminase (GGT) - slightly elevated

Coagulation Tests

Minimal elevation of test values reported for such parameters as prothrombin and Factors VII, VIII, IX and X.

Thyroid Function Tests

Protein binding of thyroxine is increased as indicated by increased total serum thyroxine concentrations and decreased T₃ resin uptake.

Lipoproteins

Small changes of unproven clinical significance may occur in lipoprotein cholesterol fractions.

Gonadotropins

LH and FSH levels are suppressed by the use of oral contraceptives. Wait two weeks after

discontinuing the use of oral contraceptives before measurements are made.

Glucose Tolerance

Oral glucose tolerance remained unchanged or was slightly decreased.

Tissue Specimens

Pathologists should be advised of oral contraceptive therapy when specimens obtained from surgical procedures and Pap smears are submitted for examination.

Non-Contraceptive Benefits of Oral Contraceptives

Several health advantages other than contraception have been reported.

1. Combination oral contraceptives reduce the incidence of cancer of the endometrium and ovaries.
2. Oral contraceptives reduce the likelihood of developing benign breast disease and as a result decrease the incidence of breast biopsies.
3. Oral contraceptives reduce the likelihood of development of functional ovarian cysts.
4. Pill-users have less menstrual blood loss and have more regular cycles, thereby reducing the chance of developing iron-deficiency anemia.
5. The use of oral contraceptives may decrease the severity of dysmenorrhea and premenstrual syndrome and may improve acne vulgaris, hirsutism and other androgen-mediated disorders.
6. Oral contraceptives decrease the incidence of acute pelvic inflammatory disease and thereby reduce as well the incidence of ectopic pregnancy.
7. Oral contraceptives have potential beneficial effects on endometriosis.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Combination hormonal contraceptives act by the suppression of gonadotropins. The primary mechanism of action is inhibition of ovulation, but other alterations include impaired sperm penetration and “spinnbarkeit” of the cervical mucus, and changes to the endometrium to reduce the likelihood of implantation. Receptor binding studies, as well as studies in animals and humans, have shown etonogestrel, the biologically active metabolite of desogestrel, combines high progestational activity with minimal intrinsic androgenicity. Desogestrel (DSG) in combination with ethinyl estradiol (EE) does not counteract the estrogen-induced increase in SHBG resulting in lower serum levels of free testosterone.

10.2 Pharmacodynamics

The contraceptive effect of COCs is based on the interaction of various factors, the most important of which are seen as the inhibition of ovulation and the changes in the cervical secretion.

Desogestrel, the progestogen component of desogestrel and ethinyl estradiol tablets, displays low androgenic activity in relation to its progestogenic effects and may increase the HDL/LDL ratio and apoprotein A-1/B ratio without affecting HDL2. Like other oral contraceptives, these changes in lipid profile can be associated with an increase in triglycerides.

Animal and *in vitro* pharmacology

Animal pharmacology and *in vitro* receptor binding studies indicate that 3-k-desogestrel, the biologically active metabolite, is a highly selective progestational agent (see table below) with no estrogenic effects, and only residual androgenicity.

Table 7 – COMPARISON OF RELATIVE BINDING AFFINITY OF DESOGESTREL, 3-k-DESOGESTREL AND PROGESTERONE FOR THE PROGESTERONE RECEPTOR IN UTERINE CYTOSOL.*

	RABBIT MYOMETRIUM	HUMAN MYOMETRIUM
Desogestrel	5	2
3-K-desogestrel	111	113
Progesterone	32	18

*Binding affinities were determined at 4NC using the reference standard 16 α -ethyl-21-hydroxy-9-nor-pregn-4-ene-3, 20-dione.

Desogestrel and its metabolites, other than 3-k-desogestrel and 3-keto-5 α -H-desogestrel, display minimal binding affinity for the androgen receptor with respect to dihydrotestosterone, as studied in intact MCF-7 cells. The binding affinity of both 3-k-desogestrel and 3-keto-5 α -H-desogestrel is approximately 1/10 of 5 α -dihydrotestosterone; suggesting a low androgenic activity. The binding affinity for the androgen receptor in intact MCF-7 cells as displayed by 3-k-desogestrel was also significantly lower than that of other progestogens.

The "selectivity index" (progestogen/androgen receptor binding affinity ratio) for 3-k-desogestrel in intact MCF-7 cells is higher than any other progestogen.

Oral desogestrel displays weak androgenic activity, approximately 0.05 the activity of 17 α -methyl-testosterone, in orchidectomized rats, using the Herschberger test.

10.3 Pharmacokinetics

Desogestrel (DSG) is rapidly and almost completely absorbed and converted into 3-keto-desogestrel, (3-K-DSG), its biologically active metabolite. After a single dose of desogestrel and ethinyl estradiol tablets, maximum concentrations of 3-K-DSG of approximately 6 pmol/mL are reached at 1.6 hours. The area under the curve (AUC_{0-∞}) is approximately 59 pmol/mL·hr after a single dose. At steady state, attained from at least day 19 onwards, maximum concentrations of approximately 18 pmol/mL are reached at 1.4 hours. The minimum plasma levels of 3-K-DSG

at steady state are approximately 4 pmol/mL. The AUC₀₋₂₄ at steady state is approximately 161 pmol/mL·hr. The relative bioavailability of 3-K-DSG is approximately 84%. The elimination half-life for 3-K-DSG is approximately 38 hours at steady state.

Major phase I metabolites are 3 α -OH-desogestrel, 3 β -OH-desogestrel, and 3 α -OH-, 5 α -OH-desogestrel. These degradation products are in part further converted by conjugation (phase II metabolism) into polar metabolites, mainly sulfates and glucuronides. Approximately 48% of 3-K-DSG is recovered unchanged in urine within 24 hours.

Ethinyl estradiol (EE) is rapidly and almost completely absorbed. After a single dose of desogestrel and ethinyl estradiol tablets, maximum concentrations of EE of approximately 0.3 pmol/mL are reached at 1.6 hours. The AUC_{0-∞} is about 4.9 pmol/mL·hr after a single dose. At steady state, attained from at least day 19 onwards, maximum ethinyl estradiol concentrations of approximately 0.5 pmol/mL are reached at about 1.4 hours. The minimum serum levels of ethinyl estradiol at steady state are about 0.08 pmol/mL. The AUC₀₋₂₄, at steady state is approximately 4.6 pmol/mL·hr. The relative bioavailability is approximately 83% and the elimination half-life about 26 hr at steady state.

Ethinyl estradiol is subject to a significant degree of presystemic conjugation (phase II metabolism). Ethinyl estradiol escaping gut wall conjugation undergoes phase I metabolism and hepatic conjugation (phase II metabolism). Major phase I metabolites are 2-OH-ethinyl estradiol and 2-methoxy-ethinyl estradiol. Sulfate and glucuronide conjugates of both EE and phase I metabolites, which are excreted in bile, can undergo enterohepatic circulation.

Absorption

Desogestrel (DSG) is rapidly and almost completely absorbed and converted into etonogestrel, (ENG), its biologically active metabolite. Following oral administration, the relative bioavailability of desogestrel, compared to solution, as measured by serum levels of etonogestrel, is approximately 100%. Ethinyl estradiol is rapidly and almost completely absorbed. When the lowest and highest tablet strengths, 0.100 mg desogestrel/0.025 mg ethinyl estradiol and 0.150 mg desogestrel/0.025 mg ethinyl estradiol, were compared to solution, the relative bioavailability of ethinyl estradiol was 92% and 98% respectively. The effect of food on the bioavailability of desogestrel and ethinyl estradiol tablets following oral administration has not been evaluated.

Distribution

Etonogestrel, the active metabolite of desogestrel, was found to be 98% protein bound, primarily to sex hormone-binding globulin (SHBG). Ethinyl estradiol is primarily bound to plasma albumin. Ethinyl estradiol does not bind to SHBG, but induces SHBG synthesis. Desogestrel, in combination with ethinyl estradiol, does not counteract the estrogen-induced increase in SHBG, resulting in lower serum levels of free testosterone.

Metabolism

Desogestrel: Desogestrel is rapidly and completely metabolized by hydroxylation in the

intestinal mucosa and on first pass through the liver to etonogestrel. In vitro data suggest an important role for the cytochrome P450 CYP2C9 in the bioactivation of desogestrel. Further metabolism of etonogestrel into 6 β -hydroxy, etonogestrel and 6 β -13ethyl-dihydroxylated as major metabolites is catalyzed by CYP3A4. Other metabolites (i.e., 3 α -OH-desogestrel, 3 β -OH-desogestrel, and 3 α -OH-5 α -H-desogestrel) also have been identified and these metabolites may undergo glucuronide and sulfate conjugation.

Ethinyl estradiol: Ethinyl estradiol is subject to a significant degree of presystemic conjugation (phase II metabolism). Ethinyl estradiol, escaping gut wall conjugation, undergoes phase I metabolism and hepatic conjugation (phase II metabolism). Major phase I metabolites are 2-OH-ethinyl estradiol and 2-methoxy-ethinyl estradiol. Sulfate and glucuronide conjugates of both ethinyl estradiol and phase I metabolites, which are excreted in bile, can undergo enterohepatic circulation.

Elimination

Etonogestrel and ethinyl estradiol are primarily eliminated in urine, bile and feces. At steady state, on Day 21, the elimination half-lives of etonogestrel and ethinyl estradiol are 37.1 \pm 14.8 hours and 28.2 \pm 10.5 hours, respectively.

Special Populations and Conditions

Race

There is no information to determine the effect of race on the pharmacokinetics of desogestrel and ethinyl estradiol tablets.

Hepatic Insufficiency

No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of desogestrel and ethinyl estradiol tablets. However, steroid hormones may be poorly metabolized in patients with impaired liver function (see [7 WARNINGS & PRECAUTIONS](#)).

Renal Insufficiency

No formal studies were conducted to evaluate the effect of renal disease on the disposition of desogestrel and ethinyl estradiol tablets.

11 STORAGE, STABILITY AND DISPOSAL

Store between 15-30°C.

Keep in a safe place out of the reach of children and pets.

12 SPECIAL HANDLING INSTRUCTIONS

Any unused product or waste material should be disposed of in accordance with local requirements.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

I. Progestogen


Proper name: Desogestrel

Chemical name: 17 (α)- 13- Ethyl-11-methylene 18, 19-dinor-pregn-4-en-20-yn-17-ol

Molecular formula: $C_{22}H_{30}O$

Molecular mass: 310.48

Structural formula:



Physical Form: White, crystalline powder

Solubility: Solubility at 20°C: n-Hexane: 40 mg/ml

Ethanol (96%): > 200 mg/ml

Ethyl acetate: > 150 mg/ml

Water: practically insoluble

Melting Point: 110-112°C

II. Estrogen


Proper name: Ethinyl Estradiol

Chemical name: 19-Nor-17 α -pregna-1,3,5(10)-trien-20-yne-3,17-diol

Molecular formula: C₂₀H₂₄O₂

Molecular mass: 296.4

Structural formula:



Physical Form: White, crystalline powder

Solubility: Soluble in ethanol, ether, acetone, chloroform, practically insoluble in water.

Melting Point: 182-184°C

14 CLINICAL TRIALS

14.1 Clinical Trials by Indication

Conception control

Table 8 – Summary of patient demographics for pivotal clinical trials (Conception control)

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
1425	Multicentre trial, Open, noncomparative, Safety and Efficacy study Day 1 start	Tablet Oral 0.150 mg DSG + 0.030 mg EE, qd for 21 days followed by 7 days	1613	See note below*	Female

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
		tablet-free			
012-012	Multicentre trial Open label, Noncomparative, Safety and Efficacy study Sunday start	Tablet Oral 0.150 mg DSG + 0.030 mg EE, qd for 21 days followed by 7 days tablet-free 6 cycles duration	604	24.9 (18-35)	Female
012-013	Multicentre trial Open label, noncomparative, Safety and Efficacy study Switchers only	Tablet Oral 0.150 mg DSG + 0.030 mg EE, qd for 21 days followed by 7 days tablet-free 12 cycles duration	397	24.9 (18-35)	Female
012-010	Open, noncomparative Safety and Efficacy study Sunday start	Tablet Oral 0.150 mg DSG + 0.030 mg EE, qd for 21 days followed by 7 days tablet-free 6 cycles duration	205	24.7 (18-35)	Female
012-002	Multicentre trial Open label, noncomparative, Safety and Efficacy study Day 1 start	Tablet Oral 0.150 mg DSG + 0.030 mg EE qd for 21 days followed by 7 days tablet-free 26 cycles duration	1195	23.6 (16-35)	Female

DSG = Desogestrel; EE = Ethinyl Estradiol; qd = daily dosing

*Data does not allow for mean age calculation. Majority of women were less than 30 years of age (78 percent).

Extensive clinical experience, in excess of 125,000 cycles in published reports alone, has documented the efficacy of desogestrel and ethinyl estradiol tablets.

Table 9 – NUMBER OF STUDIES, NUMBER OF SUBJECTS EXPOSED, ESTIMATED MINIMUM EXPOSURE AND NUMBER OF PREGNANCIES BY STUDY SIZE

STUDY SIZE	NUMBER OF STUDIES	TOTAL ENROLLED	CALCULATED MINIMUM EXPOSURE (#CYCLES) ^a	TOTAL NUMBER OF PREGNANCIES
>500	6	53,773	106,399	5
201-500	8	2,514	11,380	2
101-200	4	437	689	0
51-100	9	704	2,174	1
26-50	27	970	1,762	0
1-25	80	1,058	2,804	0
Total	134	59,456	125,208	8

^a For the purpose of estimation of extent of exposure, it is assumed that dropouts were evenly distributed over the interval of observation (if 60 subjects discontinued over 6 months, it is assumed that 10 discontinued each month). Several studies provided inadequate information on the number of subjects at subsequent visits. Therefore, the actual number of cycles is likely to be substantially larger.

In addition, several well controlled studies were designed to determine the efficacy and safety of desogestrel and ethinyl estradiol tablets. One of these involved 1,195 patients who completed a total of 11,426 cycles.

(a) Pearl Index

The observed Pearl Index among desogestrel and ethinyl estradiol tablets users compares favourably to what has been reported for other low dose oral contraceptives. Nine patients participating in this study became pregnant. User failure accounted for all of these in-treatment pregnancies. Consequently, the Pearl Index for method failure is 0.00.

N	CYCLES	PEARL INDEX	
		METHOD	TOTAL
1,195	11,656	0.00	0.92

(b) Life Table estimates

Table 10 – The annual cumulative life-table pregnancy rate is estimated as 1.0/100 women years.

CYCLE	PATIENTS	NO OF PREGNANCIES	CUMULATIVE PREG RATE/100 WOMEN
3	1037	4	0.39
6	904	4	0.82
9	734	0	0.82
12	525	1	1.00
15	307	0	1.00
18	139	0	1.00
23	9	0	1.00

(c) Cycle control

During the course of the study, 18 subjects (1.5%) discontinued due to menstrual problems. Absence of withdrawal bleeding (AWB) occurred in 1.7% of the cycles, while intermenstrual bleeding (IM) occurred in 8.0% of the total cycles. Both AWB and IM occurred more frequently during the first cycles of usage when compared to subsequent cycles. Spotting was more common than breakthrough bleeding (5.6% versus 2.5% of the cycles).

Table 11 – INCIDENCE BY CYCLE OF INTERMENSTRUAL BLEEDING AND ABSENCE OF WITHDRAWAL BLEEDING

Cycle	STARTERS			SWITCHERS		
	N	IM (%)	AWB (%)	N	IM (%)	AWB (%)
1	467	19.3	3.4	578	12.3	3.1
2	446	8.1	1.4	561	10.7	1.8
3	420	9.3	2.6	532	10.3	2.3
6	350	8.6	0.6	479	6.9	1.2
12	164	6.7	3.7	276	6.5	0.4

- intermenstrual bleeding (IM) was defined as any bleeding and/or spotting that started during the pill-taking interval that was not early or continued withdrawal bleed;
- absence of withdrawal bleeding (AWB) was defined as no bleeding and/or spotting episode that began during or continued into the pill-free interval;

Table 12 – INCIDENCE BY CYCLE OF BREAKTHROUGH BLEEDING (BTB) AND SPOTTING (BTS)

Cycle	STARTERS			SWITCHERS		
	N	BTB (%)	BTS (%)	N	BTB (%)	BTS (%)
1	467	1.5	17.8	578	1.4	11.1
2	446	2.2	5.8	561	3.4	7.5
3	420	4.0	5.5	532	3.2	7.5
6	350	3.4	5.4	479	2.5	4.6
12	164	2.4	4.3	276	2.2	4.7

- breakthrough bleeding (BTB) was defined as any bleeding episode that occurred during the pill-taking interval that was not early or continued withdrawal bleed;
- breakthrough spotting (BTS) was defined as any spotting episode that occurred during the pill-taking interval that was not early or continued withdrawal bleed;

The results indicate that cycle control with desogestrel and ethinyl estradiol tablets is generally excellent, resulting in very few dropouts due to irregular bleeding or to absence of withdrawal bleeding, these results are very similar to those obtained with other oral contraceptives.

(d) Lipid Metabolism

A causal relationship between ischemic heart disease and unfavourable plasma lipid/lipoprotein profiles, specifically, a high LDL/HDL ratio, is now widely accepted on the basis of epidemiologic, biochemical and other evidence. It has also been demonstrated that androgens influence the lipid/lipoprotein ratio unfavourably, while estrogens have a beneficial effect, largely by increasing HDL2 and, to a lesser extent, by reducing LDL levels. Major adverse or counteractive effects on the beneficial action of estrogen are therefore of fundamental importance in any long-term medication.

Desogestrel and ethinyl estradiol tablets increased HDL-C levels, decreased LDL-C, but left HDL2 and Apo B unchanged. Thus there was no significant effect on the HDL2/LDL-C ratio. Like other oral contraceptives, desogestrel and ethinyl estradiol tablets can be associated with an increase in triglyceride plasma levels.

Table 13 – NUMBER OF STUDIES DEMONSTRATING A PARTICULAR EFFECT ON LIPOPROTEIN METABOLISM AFTER 2 TO 4 MONTHS OF USE

		Desogestrel and ethinyl estradiol tablets
Total Cholesterol	No Change	12
	Increase	0
Triglycerides	No Change	4

	Increase	5
LDL-C	No Change	5
	Increase	0
HDL-C	Decrease	0
	No Change	5
	Increase	7

14.2 Comparative Bioavailability Studies

A randomized, two-period, two-treatment, single dose (2 x 0.15 mg/0.03 mg), crossover comparative bioavailability study of FREYA 28 (Mylan Pharmaceuticals ULC) and MARVELON 28® (Organon Canada Ltd.) was performed in healthy, human, female subjects under fasting conditions. A summary of the comparative bioavailability data based on etonogestrel (active metabolite of desogestrel) and ethinyl estradiol from 28 subjects that were included in the statistical analysis are presented in the following tables:

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Etonogestrel (2 x 0.15 mg/0.03 mg) Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test ¹	Reference ²	% Ratio of Geometric Means	90 % Confidence Interval
AUC _{0-72h} (pg•h/mL)	43928.20	43526.62	100.9	96.4 – 105.6
	46072.20 (35.16)	45385.87 (29.59)		
C _{max} (pg/mL)	4140.83	4170.39	99.3	91.3 – 108.0
	4306.31 (29.39)	4466.83 (37.91)		
T _{max} ³ (h)	1.50 (0.75 – 3.00)	2.00 (1.00 – 4.00)		

¹ FREYA 28 (desogestrel/ethinyl estradiol) tablets, 0.15 mg/0.03 mg (Mylan Pharmaceuticals ULC)

² MARVELON 28® (desogestrel/ethinyl estradiol) tablets, 0.15 mg/0.03 mg (Organon Canada Ltd.)

³ Expressed as the median (range) only

Due to the long elimination half-life of etonogestrel, AUC_i and T_{1/2} could not be accurately calculated from the data obtained in this study.

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Ethinyl Estradiol (2 x 0.15 mg/0.03 mg) Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test ¹	Reference ²	% Ratio of Geometric Means	90 % Confidence Interval
AUC _T (pg•h/mL)	1921.43 2047.68 (41.26)	1963.41 2037.42 (34.94)	97.9	90.6 – 105.7
AUC _I (pg•h/mL)	2125.37 2380.31 (70.37)	2135.95 2048.72 (20.66)	99.5	94.8 – 104.4
C _{max} (pg/mL)	190.73 199.41 (29.34)	191.57 199.75 (28.52)	99.6	92.7 – 106.9
T _½ ³ (h)	17.58 (71.58)	15.57 (17.76)		
T _{max} ⁴ (h)	1.50 (0.75 – 3.00)	1.50 (1.00 – 2.00)		

¹ FREYA 28 (desogestrel/ethinyl estradiol) tablets, 0.15 mg/0.03 mg (Mylan Pharmaceuticals ULC)

² MARVELON 28® (desogestrel/ethinyl estradiol) tablets, 0.15 mg/0.03 mg (Organon Canada Ltd.)

³ Expressed as arithmetic mean (CV %) only

⁴ Expressed as the median (range) only

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General toxicology:

Acute Toxicity Studies:

Acute single dose studies were conducted in both rats and mice, with desogestrel + ethinyl estradiol and desogestrel alone, to determine the upper limits of tolerance and to assess specific signs of toxicity. Both compounds were dosed orally by gavage or intraperitoneal as aqueous suspensions. The oral dosage level of 2000 mg/kg was about 6 x 10⁵ times the projected human clinical dose. The intraperitoneal dosage was 500 mg/kg. Groups of 10 males and 10 females were tested with desogestrel + ethinyl estradiol and groups of 6 males and 6 females with desogestrel alone. The animals were observed for 7 days and then necropsied.

None of the test animals died during the oral or intraperitoneal studies. The oral dosed mice and rats had temporary signs of reduced activity, some motor incoordination, diminished food consumption, and other nonspecific signs related to the large dose of the test material.

Likewise, mice and rats dosed intraperitoneal showed similar signs. Some evidence of serositis (localized peritoneal irritation) was associated with the test substances.

These data are consistent with published information on other contraceptive steroids which indicate that steroids in general have a low level of toxicity in single dose acute animal studies.

Multidose Toxicity Studies

The objective of the multidose toxicity studies was to determine whether the chronic oral administration of either desogestrel + ethinyl estradiol or desogestrel alone to mice, rats, dogs, and monkeys would induce either reversible or irreversible systemic adverse effects or cause the development of benign or malignant neoplasms. Desogestrel + ethinyl estradiol, in a ratio of 2.5:1, was employed in most multidose toxicity and multidose tumorigenicity toxicity studies and in a ratio of 5:1 in 52-, 104-week and 3-year studies in dogs and monkeys. The test compounds were administered orally by gavage to mice and rats, orally by tablet or capsule to dogs, and orally by soft drink or by intubation to monkeys.

The protocol for each of these studies was typical of that used for multidose toxicity tests in general. The doses were multiples of the human dose and generally calculated to be 2, 20, and 200 times the expected human usage levels in most multidose and tumorigenicity studies in mouse, rat and dog. In shorter studies, the duration of treatment was 26 or 52 weeks with a 4 to 13 week recovery period incorporated into the study design. In the 52-, 104-week and 3-year dog and monkey studies dose levels were 1, 10, 25 and 2, 10, and 50 times the human dose respectively.

The following table lists the study duration, species tested, and the test compounds:

Table 14 – Multidose Toxicity Studies

Multidose Toxicity Studies				
Duration	Species	Drugs	Dose(mg/kg)	n
52 weeks	rat, dog	DSG + EE	0.005 + 0.002 ^a 0.05 + 0.02 0.5 + 0.2	70,14
	dog	DSG + EE	0.003 + 0.0006 ^b 0.03 + 0.006 0.075 + 0.015	20
	monkey	DSG + EE	0.006+0.0012 ^c 0.03 +0.006 0.15 +0.03	20
80 weeks	mouse	DSG + EE	see ^a	112

Multidose Toxicity Studies				
Duration	Species	Drugs	Dose(mg/kg)	n
104 weeks	rat	DSG + EE	see ^a	110
	dog	DSG + EE	see ^b	20
	monkey	DSG + EE	see ^c	20
3 years	dog	DSG + EE	see ^b	20
	monkey	DSG + EE	see ^c	20
26 weeks	rat, dog	DSG	0.00625 0.0625 0.625	64,14
52 weeks	rat, dog	DSG	0.005 ^d 0.05 0.5	60,12
81 weeks	Mouse	DSG	see ^d	112
104 weeks	Rat	DSG	see ^d	110

DSG = desogestrel EE = ethinyl estradiol

The 52-week study with desogestrel + ethinyl estradiol in rats revealed no direct treatment-associated effect on mortality. Clinical signs of treatment included alopecia and reduction of testicle size, primarily in high dose animals, which were reversible on treatment cessation. Depressed weight gain and/or decreased food consumption was present in both sexes of the intermediate and high dose animals. There was an alteration in APTT, Hb, and PCV were noted along with lowered neutrophil and lymphocyte counts. These changes are known to occur in these types of studies and were found to be reversible upon treatment cessation. No unusual changes were found in blood chemistry or urinalysis. Dose-related lower protein content of the urine in males may be attributed to the atrophic change in secondary sex organs.

Organ weight changes were consistent with those noted with other combination oral contraceptives. The liver weight was increased at 26 and 52 weeks in primarily ID and high dose animals; testes, epididymides, prostate, seminal vesicles, ovaries, uterus, adrenals, and the pituitary gland were also affected by treatment.

Microscopic tissue changes included the following: hepatocytic vacuolation and occasional foci of hepatocellular hyperplasia, especially in high dose animals; a dose-related increase in yellowish pigment in the kidney cortical tubule epithelium, and increased mineralized concretions in high dose males; atrophy of the testes, epididymides, prostate, and seminal vesicles; reduction or absence of corpora lutea in the ovaries; hyalinization or endometrial hyperplasia of the uterus; increased keratinization of the vagina in high dose females; hypertrophy and hyperplasia of the adrenal cortex with sinusoidal telangiectasis; and hypertrophy/hyperplasia of the anterior lobe of the pituitary, especially at 52 weeks in high dose animals.

The 8-week withdrawal period used in this study resulted in a partial reversal of the prior changes. All would have probably reverted to normal with a longer recovery period. There was an increased incidence of benign mammary neoplasms in all drug-treated groups.

The 52-week dog study was conducted with oral dosed desogestrel + ethinyl estradiol tablets in a ratio of 2.5:1. Three high dose mortalities occurred during the study. Two females died and the other was killed in extremis. The cause of death or morbidity was peritonitis, secondary to perforating pyometra. Clinical signs included typical skin thickening and folding with alopecia, interruption of the estrous cycle with swelling of external genitalia in females, vaginal discharge in high dose females, pendulous penile sheath in males with reduction in testicle size, enlarged and/or secretory mammary tissue in females, and 2 transient (1, intermediate dose) and 1 transient and 1 persistent nodule (1, high dose) of the mammary gland. The persistent nodule was an area of hyperplasia.

Changes in certain hematological, coagulation, blood chemistry and urinalysis parameters were neither unusual nor unexpected for this type of compound. Changes either in weight or histomorphological characteristics were noted in the primary and secondary sex organs and liver, primarily in high dose animals. All were associated with the hormonal attributes of the drug.

The multidose toxicity study in the monkey was performed at a 5:1 ratio of desogestrel to ethinyl estradiol with dosing for 21 days followed by a 7-day drug-free period. The 12-month data revealed no unexpected clinical, clinicopathological, or histomorphological findings. Typical hormonally dose-related changes occurred, such as decreased corpora lutea, secretory mammary glands, increased endocervical mucus, decreased thickness of the endometrium with secretory changes, a dose-related decrease in the thickness of the vaginal epithelium and increased pituitary weight.

The multidose studies in rats and dogs with desogestrel alone resulted in fewer alterations in the primary and secondary sex organs and other peripheral hormonally sensitive tissues.

In rats, the absence of ethinyl estradiol in the test compound resulted in expected progestational changes at 26 and 52 weeks, such as secretory changes in the uterine endometrium, mucification of the vaginal epithelium, mild glandular hyperplasia of the mammary glands, and reduced pituitary weights. In the 52-week portion of the study, a small number of benign or malignant neoplasms were observed, but none of these were causally related to the test compound.

The toxicity of multidoses of desogestrel alone in dogs resulted in no unusual or unexpected changes at 26 weeks. The liver weight in high dose animals was increased but this was due primarily to the progestogenic effect of increased glycogen storage. The uterus was increased in both size and weight due to hormonal stimulation of the endometrium and the ovaries had a lack of mature follicles and an absence of corpora lutea. The prostate weight was slightly

reduced in high dose males. Lobular development of the mammary glands was increased in intermediate and high dose females.

The 52-week segment of the dog study with desogestrel alone resulted in changes similar to those seen at 26 weeks; however, occasional small mammary nodules (5 mm or less) were present in 1 control (C), 1 low dose (LD), 1 ID, and 4 high dose animals. They disappeared in the 1 C and 2 high dose animals. The remaining nodules were found to be nonneoplastic and proved to be either smaller superficial lymph nodes or dilated ducts. The uterine stimulation was increased at 52 weeks but did not result in the death of any animal.

Four multidose toxicity studies of up to 2 years in duration were conducted in rats, dogs, and monkeys. Desogestrel + ethinyl estradiol was studied in rats, monkeys, and dogs, and desogestrel alone was studied in rats.

In rats, there was no evidence of a neoplastic response when desogestrel was administered alone, however, increased evidence of benign mammary neoplasms were evident in all desogestrel + ethinyl estradiol treated groups. Other clinical, clinicopathological, and histopathological changes were attributable to the hormonal influences of either desogestrel or its combination with ethinyl estradiol.

The 2-year dog study utilized a 5:1 desogestrel + ethinyl estradiol ratio. The test compound was dosed at 1, 10 and 25 times the human dosage levels for 21 days with a 7-day drug-free period. There was evidence of the following: suppression of the estrous cycle in intermediate and high dose animals, an increased incidence of mammary gland development and secretory activity similar to those observed in the normal metestrous phase of the cycle; decreased AP in high dose dogs, and a single focus of ductal epithelial hyperplasia in 1 low dose dog. No tumorigenic effect was present.

The 2-year study of desogestrel + ethinyl estradiol in monkeys caused the expected pattern of hormonally-mediated changes. Menstrual and ovarian activity were reduced in high dose animals. Secretory activity of the mammary glands was increased in a dose-related manner in intermediate and high dose animals. Other hormonally-associated changes included: an increased fibrinogen and APTT; decreased PPT; reduced AP; increased triglycerides and cholesterol levels; and lowered albumen in intermediate and high dose animals; endometrium which was either stimulated (ID and HD) or lacked activity (some high dose animals); and increased acidophils and decreased basophils in the pituitary in intermediate and high dose animals. All of these findings are consistent with contraceptive steroid effects in the monkey.

Multidose tumorigenicity studies were conducted in the mouse (80-81 months) and rat (2 years) with either desogestrel + ethinyl estradiol or desogestrel alone, respectively. Desogestrel + ethinyl estradiol in mice resulted in a higher mortality rate; this was primarily due to the increased incidence of pituitary tumors in treated mice, especially high dose animals. Other nonneoplastic alterations occurred, but were within expected limits for a

compound of this type. Desogestrel alone in mice did not remarkably affect the mortality rate and had no influence on tumorigenicity.

Desogestrel + ethinyl estradiol in the rat, resulted in slightly increased mortality at the high dose level and contributed to a dose-dependent increase in the number of pituitary and mammary neoplasms; this increase was largely attributable to the ethinyl estradiol component.

Desogestrel alone in the rat had no influence on mortality and possibly was responsible for a slight lowering effect. Incidences of mammary and pituitary tumors were slightly lessened at the high dose level. This is in contrast to the 104-week rat study with desogestrel + ethinyl estradiol, where the differences noted were considered to have been attributable to the ethinyl estradiol component.

Three year studies were conducted in both Beagle dogs and Rhesus monkeys with desogestrel + ethinyl estradiol with a 1-and 2-year interim sacrifice in monkey and a 2-year interim sacrifice in dogs. No tumorigenic response was noted. Mammary glands of dogs had lobulo-alveolar development with limited secretory change, an expected hormonal effect. Other tissue changes as described under the 2-year interim report, limited to the primary and secondary sex organs, were associated with the hormonal activities of the combination OC.

The monkey study conducted for 3 years, with a 1-and 2-year interim sacrifice, revealed no evidence of a tumorigenic effect. The changes observed, as described at the 2-year interim studies, were typical of the hormonal activities of the combination OC and included effects on the menstrual cycle, cervical mucus and endometrial morphology.

Mutagenicity Studies

The Ames test and the rat Micronucleus test were conducted on desogestrel, either alone or in combination with ethinyl estradiol. Both assays demonstrated that neither desogestrel alone nor in combination with ethinyl estradiol exert any mutagenic effect.

Reproductive and Developmental Toxicology

Nonclinical reproductive toxicity studies included 11 studies conducted in rats and 2 studies conducted in rabbits. Desogestrel, both alone and in combination with ethinyl estradiol, was tested. These studies were conducted to assess what effect, if any, the test substance might have on the reproductive process, including; fertility and reproductive performance, teratogenicity and embryotoxicity, and perinatal and postnatal effects in the offspring.

Four segment I reproductive toxicity studies were conducted in rats; 1 study with desogestrel + ethinyl estradiol and 3 studies with desogestrel alone. The desogestrel + ethinyl estradiol study, conducted using doses of 0.5 mg desogestrel + 0.2 mg ethinyl estradiol/kg/day, demonstrated that the test compound had no adverse effect on mating and pregnancy

performance in F₀ females or on the number, anatomical features, development and fertility of the offspring.

Desogestrel alone was studied in both Sprague Dawley and CFY rats. An additional study in Sprague Dawley rats was conducted after microphthalmia was increased in CFY offspring of the desogestrel-treated dams. No increase in microphthalmia was seen in the second Sprague Dawley study. The defect was thus thought to be strain-related. In all 3 studies the contraceptive effect of desogestrel was reversible. Treatment at contraceptive and subcontraceptive dose levels did not cause any serious after effects on the dams or their offspring.

A fertility and embryotoxicity study with desogestrel + ethinyl estradiol at levels causing complete infertility, slight infertility, and no infertility, were conducted in rats. Uninterrupted daily administration of desogestrel + ethinyl estradiol, at subcontraceptive doses before and during pregnancy, reduced the number of offspring but had no effect on the quality of the F₁ generation.

Segment II embryotoxicity studies following the classical design with dosage exclusively during pregnancy and organogenesis were performed in both the rat and rabbit. A total of 5 embryotoxicity studies were conducted; 3 studies with desogestrel alone and 2 studies with desogestrel + ethinyl estradiol.

Desogestrel + ethinyl estradiol tested at high dose levels in rats and rabbits caused maternal toxicity and embryoletality, but at lower doses had no untoward reaction in the dams and no detectable effect on the course of pregnancy, embryonic mortality, or fetal morphology.

Desogestrel alone was tested in both Sprague Dawley and CFY rats and in rabbits. High dosages of desogestrel caused maternal toxicity (2-8 mg/kg) in rats, while doses of 2 to 4 mg/kg caused abortion in rabbits. Lower dosages in rats and rabbits caused no discernible effect on the course of pregnancy, embryonic mortality, or on fetal morphology.

The effects of desogestrel alone, when dosed during late pregnancy, was assessed in rats. Dose levels up to 4 mg/kg/day from days 14-20 of pregnancy caused neither masculinization of female fetuses nor feminization of male fetuses.

Segment III studies, to evaluate the possible effects on peri-and postnatal development due to transfer of drug through the milk, were conducted with desogestrel, either alone or in combination with ethinyl estradiol. Desogestrel + ethinyl estradiol caused reduced food consumption in intermediate and high dose dams. Retarded pup growth persisted until weaning in the high dose group, but there was no effect on the pre-or post-weaning physical development. Fertility of the F₁ offspring was not affected. Desogestrel alone had no effect on the treated dams, weight gain in the pups, or physical development of the pups. Fertility of the F₁ treated animals was comparable to that of the F₁ control females.

17 SUPPORTING PRODUCT MONOGRAPHS

1. MARVELON® 21 and MARVELON® 28 tablets, 0.15 mg desogestrel and 0.03 mg ethinyl estradiol, submission control 261227, Product Monograph, Organon Canada Inc. (JUL 07, 2022)

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PrFREYA 21 and PrFREYA 28 Desogestrel and Ethinyl estradiol Tablets, USP

Read this carefully before you start taking **FREYA** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **FREYA**.

Serious Warnings and Precautions

- Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels. This risk increases with age, particularly in women over 35 years of age. The risk also increases with the number of cigarettes smoked. For this reason, women who smoke and are over 35 years of age should not use FREYA.
- Birth control pills **DO NOT PROTECT** against sexually transmitted infections (STIs), including HIV/AIDS. For protection against STIs, it is advisable to use latex or polyurethane condoms AND take your birth control pills.

What is FREYA used for?

FREYA is used to prevent pregnancy in women who have had their first menstrual period (menarche).

How does FREYA work?

FREYA is a birth control pill. It is considered to be a combination oral contraceptive. This is because it contains two female sex hormones: desogestrel and ethinyl estradiol. Desogestrel/ethinyl estradiol tablets have been shown to be effective in preventing pregnancy when taken as prescribed by your healthcare professional.

Combination hormonal contraceptives like FREYA work in two ways:

- To stop the monthly release of an egg by the ovaries.
- To change the mucus produced by your cervix. This slows the movement of the sperm through the mucus and through the uterus (womb).

Effectiveness of Birth Control Pills

Combination birth control pills are more than 99 percent effective in preventing pregnancy when:

- the pill is **TAKEN AS DIRECTED**, and
- the amount of estrogen is 20 micrograms or more.

A 99 percent effectiveness rate means that if 100 women used birth control pills for one year, one woman in the group would get pregnant. The chance of becoming pregnant increases if

FREYA is not used correctly.

Other Ways to Prevent Pregnancy

There are other methods of birth control available. They are usually less effective than birth control pills. If used properly, the other methods of birth control are effective enough for many women.

The following table lists pregnancy rates for different types of birth control, including no birth control. A pregnancy rate is the number of women out of 100 who would become pregnant in one year.

Reported Pregnancies per 100 Women per Year:

Subdermal Implant	less than 1
Combination pill	less than 1 to 2
Intrauterine device (IUD)	less than 1 to 6
Condom with spermicidal foam or gel	1 to 6
Mini-pill	3 to 6
Condom	2 to 12
Diaphragm with spermicidal foam or gel	3 to 18
Spermicide	3 to 21
Sponge with spermicide	3 to 28
Cervical cap with spermicide	5 to 18
Periodic abstinence (rhythm), all types	2 to 20
No birth control	60 to 85

There are differences in these pregnancy rates. This is because not all people use birth control as carefully or as regularly as they should. This does not apply to subdermal implants or IUDs since these are implanted under the skin or in the uterus. If you are careful and use your birth control regularly, pregnancy rates should be lower. Some types of birth control will require more effort than taking a single pill every day.

What are the ingredients in FREYA?

Medicinal ingredients: desogestrel and ethinyl estradiol.

Non-medicinal ingredients:

Inactive ingredients include anhydrous lactose, colloidal silicon dioxide, polyvinyl pyrrolidone, potato starch, stearic acid and vitamin E.

FREYA 28 also contains 7 green tablets containing the following inactive ingredients: FD&C Blue No. 1, ferric oxide yellow, lactose monohydrate, magnesium stearate and polacrillin potassium.

FREYA comes in the following dosage forms:

FREYA 21:

white tablets: 0.15 mg desogestrel and 0.03 mg ethinyl estradiol.

FREYA 28:

white tablets: 0.15 mg desogestrel and 0.03 mg ethinyl estradiol.

green tablets: no active ingredients.

Do not use FREYA if:

- you are allergic to desogestrel or ethinyl estradiol or any of the non-medicinal ingredients in FREYA (see **What are the ingredients in FREYA?**)
- you have or have had a blood clot in the legs (deep vein thrombosis), lung (pulmonary embolism), eyes or somewhere else in your body, or thrombophlebitis (inflammation of the veins)
- you have the following risk factors for blood clots:
 - severe high blood pressure or blood pressure that is not under control (hypertension)
 - diabetes with complications
 - blood clot disorders such as:
 - abnormal Factor V Leiden mutation
 - activated protein C (APC) resistance
 - antithrombin-III-deficiency
 - protein C deficiency
 - protein S deficiency
 - hyperhomocysteinemia
 - prothrombin mutation G20210A
 - anti-phospholipid-antibodies
 - very high blood cholesterol or triglyceride levels
 - smoke and are above the age of 35
 - a family history of blood clot disorders
 - you have had or will have a major surgery (including to the legs, pelvis or nervous system)
 - you cannot stand or move for long periods of time, including prolonged bed rest
- you had a stroke or heart attack
- you have or had coronary artery disease (including angina) or a condition that may be a first sign of stroke (such as mini stroke, small reversible stroke, chest pains)
- you have a disease of the heart valves with complications
- you have or have had migraine headaches with or without focal aura (flashes or light, blind spots and other vision changes)
- you have or might have breast cancer
- you have a cancer of the uterus, or a cancer that is sensitive to hormones
- you have liver disease

- you have Hepatitis C Virus (HCV) and are taking the combination drug regimen ombitasvir / paritaprevir / ritonavir, with or without dasabuvir, or some other Hepatitis C drug combinations (such as glecaprevir/pibrentasvir)
- you have or have had liver tumors (cancerous or non-cancerous)
- you have or have had jaundice. This is where the skin or whites of the eyes turn yellow. This may have been related to other medicines you were taking or may have happened during pregnancy.
- you have unusual vaginal bleeding without a known reason
- you have loss of vision due to blood vessel disease of the eye
- you have or have had inflammation of the pancreas (pancreatitis) and high levels of fat in your blood (triglycerides)
- you are or think you might be pregnant

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take FREYA. Talk about any health conditions or problems you may have, including if you:

- smoke
- are overweight
- have high blood pressure
- have high cholesterol
- have or have a family history of diabetes
- have a family history of stroke, heart attack or blood clot disorders
- have or have a history of heart or kidney problems
- have a history of seizures or have epilepsy
- have a history of depression
- have a history of liver problems
- have cholestasis. This is a condition where bile flow from the liver is decreased.
- wear contact lenses
- have uterine fibroids (benign tumours of the uterus)
- have systemic lupus erythematosus. This is a disease of the immune system that affects your joints, skin, kidneys, blood cells, brain, heart and lungs.
- have inflammatory bowel disease such as Crohn's disease or ulcerative colitis
- have hemolytic uremic syndrome. This is when there is an abnormal breakdown of blood cells, which clogs the kidney.
- have sickle cell disease. This is a disease that affects haemoglobin, a molecule in red blood cells that delivers oxygen throughout the body.
- have problems with the valves in your heart and/or have an irregular heart beat
- have a condition called hereditary or acquired angioedema or if you have had episodes of swelling in body parts such as hands, feet, face, tongue and/or throat, or airway passages, if you experience difficulty swallowing, potentially with difficulty breathing. Products containing estrogens may cause or worsen hereditary and acquired angioedema.
- have porphyria. This is a disease of blood pigment that is passed down in families (inherited).

- have a history of a skin condition called chloasma (hyperpigmentation)

Other warnings you should know about:

Blood Clot in Legs, Lungs, Heart, Eyes or Brain

Women who use birth control that contains hormones are more likely to develop blood clots. Blood clots are the most common serious side effects of birth control pills. The risk for clots is highest during the first year a woman uses a hormonal birth control. The risk is also high if a woman restarts the same or new hormonal birth control. Clots can occur in many areas of the body and can lead to blindness or impaired vision as well as damage to or loss of a limb and death.

While you are taking FREYA, if you have any of the below symptoms, talk to your healthcare professional right away. These are signs of blood clots.

- sharp pain in your chest
- coughing up blood
- sudden shortness of breath
- crushing chest pain or chest heaviness
- irregular heartbeat
- sudden severe or worsening headache
- feeling full
- vomiting
- dizziness, trouble walking
- fainting, seizures
- anxiety, confusion
- changes in vision
- changes in speech
- pain and / or swelling in your calf
- weakness or numbness in your face, arm or leg
- sudden pain, swelling and slight blue or red discoloration of an arm or leg
- discomfort radiating to your back, jaw, throat or stomach

Blood clots can develop whether or not you are using hormones for birth control. They can also happen if you are pregnant. The risk is higher in users of CHCs, including FREYA than in non-users, but it is not as high as the risk during pregnancy. You should talk to your healthcare professional about the available options.

Cancer

Using birth control pills may increase the risk of certain cancers including cancer of the breast, cervix and liver.

Breast cancer: The risk of breast cancer in women increases as you get older. It also increases if there is family history of breast cancer, meaning if your mother or sister have or had breast

cancer. Other factors that increase your risk for breast cancer are being obese, never having children, or having your first full-term pregnancy at a late age.

If you have breast cancer now, or had it in the past, do not use birth control pills. The hormones in these pills can affect some cancers.

Some women who use birth control pills may have a higher risk of developing breast cancer before menopause. These women may have used birth control pills for a long time (more than eight years), or may have started using birth control pills at an early age.

In a few women, using of birth control pills can speed up the growth of a breast cancer that has not yet been found. Finding breast cancer early can reduce the effect of the cancer on a woman's life expectancy. The risks for breast cancer related to using birth control pills seem to be small. You should, however, have a healthcare professional check your breasts at least once per year.

While you are taking FREYA, check your breasts often. See your healthcare professional if you notice any changes, such as:

- dimpling or sinking of the skin
- changes in the nipple
- any lumps you can see or feel

Cervical cancer: Women who use birth control pills may have a higher chance of getting cervical cancer. However, this may be due to other reasons including infection with the Human Papilloma Virus (HPV). HPV is an important risk factor for cervical cancer. However, it is possible that oral birth control pills may also cause such cancers.

Liver cancer: Liver cancer (hepatocellular carcinoma) and liver tumours may be linked to oral birth control pills. The risk for liver cancer increases the longer these pills are used. However liver tumours are extremely rare. If you feel severe abdominal pain or find a lump in your abdomen, talk to your healthcare professional right away.

Do not use FREYA if you have a history of liver tumors (cancerous or noncancerous).

Gallbladder Disease

The risk for gallbladder disease that needs surgery is higher in women using birth control pills. The risk is highest in the first year of use and increases the longer these pills are used.

Vaginal Bleeding

Breakthrough bleeding or spotting sometimes happens in women using birth control pills including FREYA. This is blood coming from the vagina between periods. It is most likely to happen in the first months of starting a birth control pill. If the bleeding is heavy or does not stop, talk to your healthcare professional.

While you are taking FREYA you may not get your period each month. If you were not taking FREYA as directed by your healthcare professional, you should have a pregnancy test. This will rule out if the missed period is because you are pregnant.

Pregnancy, Breastfeeding, Miscarriage and Abortions

Use in pregnancy: Birth control pills should not be taken by pregnant women. Stop taking FREYA if you get pregnant. You should talk to your healthcare professional about risks to your unborn child from any medication taken during pregnancy.

Use after pregnancy, miscarriage or an abortion: You will be at increased risk for blood clots. Your healthcare professional will tell you when to start using FREYA after childbirth, miscarriage or an abortion.

Pregnancy after stopping FREYA: You will have a menstrual period when you stop using FREYA. Wait until after your next period before getting pregnant. This will help to better date the pregnancy. Talk to your healthcare professional about other forms of birth control you can use during this time.

Breastfeeding: If you are breastfeeding, talk to your healthcare professional before starting the birth control pill. Other types of birth control, instead of a birth control pill, are recommended until your baby has stopped breastfeeding. The hormones in the pill may lower the amount and quality of your breast milk. This may not happen, however, if you wait until after breastfeeding is established.

Skin Conditions

Chloasma may develop while you are using FREYA. This appears as yellowish-brown patches on the skin, particularly of the face. It is more likely to happen if you have previously had chloasma gravidarum. This is when these patches appear on the skin of the face during pregnancy. This is commonly known as “the mask of pregnancy”. If you have or had chloasma, avoid too much exposure to the sun while using FREYA.

Surgery

Tell your healthcare professional if you are scheduled for surgery. You may need to stop using FREYA four weeks before surgery and during prolonged bed rest. You may need to wait for at least two weeks after surgery before restarting FREYA.

Check-Ups and Tests

Before starting FREYA, you will need to have examinations and tests. Your healthcare professional will conduct a physical exam. They will examine your breasts, liver, arms and legs. They will conduct a pelvic exam which includes a PAP smear. Your healthcare professional will also ask you some questions about your personal health history and that of your close relatives. They will also measure your blood pressure and do blood tests.

While you are taking FREYA, you will need regular check-ups with your healthcare professional. Your first check-up should be about three months after starting FREYA. Afterward, you will see your healthcare professional at least once a year. At these visits, your healthcare professional will conduct physical and internal exams. They will also measure your blood pressure and do blood tests.

If you are scheduled for any laboratory tests, be sure to tell your healthcare professional that you are taking FREYA. If you see a different healthcare professional be sure to tell them that you are taking FREYA. This is because birth control pills can affect some blood tests.

FREYA may not work as well as it should to prevent pregnancy if you:

- miss pills
- don't take your pills as directed by your healthcare professional
- have gastrointestinal problems
- are taking certain medicines

If this happens, you should use another method of birth control, like condoms (barrier method). Do this while taking FREYA and until you start a new pack of FREYA.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

Certain drugs may interact with birth control pills (including FREYA) and prevent them from working properly. This can make them less effective in preventing pregnancy or cause unexpected bleeding (spotting or breakthrough bleeding). Birth control pills may also interfere with how other drugs work.

The following may interact with FREYA:

- drugs used for the treatment of epilepsy including primidone, phenytoin, barbiturates (e.g., phenobarbital, carbamazepine, oxcarbazepine, lamotrigine, topiramate, felbamate)
- drugs used for the treatment of tuberculosis including rifampicin, rifabutin
- drugs used for the treatment of HIV infections or AIDS including ritonavir, nelfinavir, nevirapine, efavirenz
- drugs for Hepatitis C Virus infections including ombitasvir, paritaprevir, ritonavir, with or without dasabuvir, boceprevir, telaprevir, and some other Hepatitis C drug combinations (such as glecaprevir / pibrentasvir)
- drugs used to treat bacterial infections including nitrofurantoin, erythromycin, clarithromycin, chloramphenicol, neomycin, sulfonamides, troleandomycin
- drugs used to treat fungal infections including griseofulvin, fluconazole, itraconazole, ketoconazole
- drugs used to lower cholesterol including clofibrate
- drugs used to prevent blood clots
- St. John's wort, an herbal product used to treat depression and other conditions

- drugs used to treat high blood pressure including guanethidine, methyldopa, beta-blockers, diltiazem
- drugs used to treat high blood pressure in the blood vessels between the heart and lungs (pulmonary hypertension) including bosentan
- drugs used to treat diabetes including insulin and oral drugs that lower blood sugar
- drugs used to treat fever, pain or inflammation including prednisone, phenylbutazone, acetaminophen, ASA, antipyridine, meperidine
- drugs used to help you relax or sleep including barbiturates, glutethimide, meprobamate, chlordiazepoxide, lorazepam, oxazepam, diazepam, phenothiazines, reserpine
- drugs used to treat depression including clomipramine
- drugs used to treat allergies including antihistamines
- drugs used to treat migraine headaches
- some nutritional supplements including Vitamin E, Vitamin B12, folic acid
- drugs used to help prevent organ rejection including cyclosporine
- alpha-II adrenoreceptor agents including clonidine
- a drug used to help treat bleeding called aminocaproic acid
- drugs used to treat lung diseases such as asthma and COPD (bronchitis, emphysema) including betamimetic agents (e.g. isoproterenol), theophylline

Antacids may affect how FREYA is absorbed in your body. If you need to use antacids, like TUMS, take them 2 hours before or 2 hours after taking FREYA.

The effects of caffeine and alcohol may be increased. This is because birth control pills affect how these are metabolized.

If you are taking medicines or herbal products that might make FREYA less effective, a barrier method of birth control should also be used. Since the effect of other medicines on FREYA may last up to 28 days after stopping the medicine, you must use the additional barrier method of birth control for that long.

Do not use FREYA if you have Hepatitis C and are being treated with ombitasvir / paritaprevir / ritonavir, with or without dasabuvir or some other Hepatitis C drug combinations (such as glecaprevir/pibrentasvir). Using these drugs at the same time as FREYA can cause problems with your liver, such as an increase in the ALT liver enzyme. You can usually start FREYA about 2 weeks after finishing treatment with these combination drugs used for Hepatitis C, but talk to your healthcare professional before taking FREYA.

How to take FREYA:

1. Be sure to read these directions:


- before you start taking your pills, and
- any time you are not sure what to do.

2. Decide with your healthcare professional what the best day is for you to start taking your first pill. Pick a time of day that will be easy to remember.

3. **Look at your pill pack:**

- There are two types of pill packs for FREYA:


A. FREYA 21



The FREYA 21 pill pack has:

- 21 white pills that contain hormones

B. FREYA 28



The FREYA 28 pill pack has:

- 21 white pills that contain hormones
- 7 green pills that contain no hormones

- Check the pill pack for:

- where to start taking pills; and
- the order to take the pills. Follow the arrows.

4. **The first day of your menstrual period (bleeding) is day 1 of your cycle.** Your healthcare professional may tell you to start taking the pills on Day 1 or on the first Sunday after your period begins. If your period starts on Sunday, start that same day.


5. **A. FREYA 21:**
 Take one white pill at approximately the same time every day for 21 days. Then take no pills for 7 days. Begin a new pack after 7 days of no pills. Your period should occur during the 7 days that you are not taking pills. You must not be off the pills for more than seven days in a row.

- B. FREYA 28:**
 Take one pill at approximately the same time every day for 28 days. Begin a new pack the next day, **NOT MISSING ANY DAYS**. Your period should occur during the last seven days of using that pill pack, while you are taking the green pills.


6. Select the appropriate day-of-the-week label strip. It starts with Day 1 of your menstrual period (for Day 1 starts) or Sunday (for Sunday starts). Apply it to the blister pack above the first row of tablets. This can help remind you to take your pill every day.

7. **Taking FREYA:**
 - Take FREYA exactly as directed by your healthcare professional.
 - Take FREYA with or without food.
 - Take your pill at approximately the same time every day. Try to associate taking your pill with a regular activity like eating a meal or going to bed. This will help you remember to take it.
 - Start taking FREYA on either:
 - Day 1 of your period. This is called “Day 1 Start”; or
 - The first Sunday after your period starts. This is called “Sunday Start”. If your period starts on Sunday, start that same day.

- Take FREYA 21 according to this schedule:



- Take 1 white pill each day for 21 days in a row.
 - Then, take no pills for 7 days.
 - Start the next pack after 7 days of no pills.
 - You must not be off the pills for more than 7 days in a row.
- Take FREYA 28 according to this schedule:



- Take 1 white pill each day for 21 days in a row. You should always begin a pack by starting with the white pills. You should always take the white pills first.
 - Then, take 1 green pill each day for 7 days in a row.
 - Start the next pack on the day after your last green pill. Do not wait any days between packs.
- Be sure to use all the pills in each pack.
 - Do not skip any of the pills even if you are spotting or bleeding between monthly periods or feel sick to your stomach.
 - Do not skip pills even if you do not have sex very often.
 - If you start FREYA after Day 1 of your period (Sunday Start), use an extra barrier method of birth control (such as a condom) for the first 7 days of your first cycle of FREYA.

You might notice bleeding 2 to 4 days after the last white pill. The bleeding might not finish before you start the next pack. This is normal. If this happens, do not stop taking FREYA. These symptoms will usually go away. If they remain for a long time, talk to your healthcare professional.

You may miss your period while you are taking FREYA. If you have been having regular periods and then do not have a period for two or more cycles, you may be pregnant. Talk to your healthcare professional if this happens.

If you vomit within 4 hours after taking a white pill, take **a new pill as soon as possible**. A new pill should be taken within 24 hours of the usual dose time. Take the next pill at the usual dose

time. If it has been more than 24 hours since the last pill was taken, see "**Missed Dose**" below for more instructions.

Switching to FREYA from a different type of birth control:

- For any switch, always use a second barrier method of birth control (such as condoms) for the first 7 days of taking FREYA.
- If you are switching from another combined oral birth control pill, talk to your healthcare professional about when to start taking FREYA.
- If you are switching from minipill (progestogen only) birth control, start taking FREYA on the next day.
- If you are switching from a type of birth control that is implanted, start taking FREYA on the day the implant is taken out.
- If you switch from a type of birth control that is injected into your body, start taking FREYA on the day the next injection would happen.

Usual dose:

FREYA 21: 21 white pills (active)

Take one (1) pill per day for 21 days. Then take no pills for 7 days.

FREYA 28: 21 white pills (active), 7 green pills (inactive)

Take one (1) white pill per day. When all 21 white pills are done, take one (1) green pill per day for 7 days.

Overdose:

If too many birth control pills are taken at one time, nausea, vomiting, breast tenderness, dizziness, abdominal pain, fatigue, drowsiness and vaginal bleeding in women are possible.

If you think you, or a person you are caring for, have taken too much FREYA, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you miss white pills, you could get pregnant. The more pills you miss, the more likely you are to get pregnant. This is especially true if you miss taking the first few or the last few white pills in a pack.

Missing pills can cause you to have some spotting or light bleeding, even if you take the missed pills.

If you forget more than one pill two months in a row, talk to your healthcare professional about ways to make pill-taking easier or about using another method of birth control.

The following chart tells you what to do if you miss taking one or more birth control pills. Match the number of pills missed with the appropriate starting time for the type of pill pack. If you miss one or more white pills and do not have a period that month, you may be pregnant. If this happens talk to your healthcare professional.

Sunday Start	Day 1 Start
Miss 1 pill	Miss 1 pill
<ol style="list-style-type: none"> 1. Take the missed pill as soon as possible and take the next pill at the usual time. This means that you might take 2 pills in one day. 2. Keep taking one pill a day until the pack is finished. 	<ol style="list-style-type: none"> 1. Take the missed pill as soon as possible and take the next pill at the usual time. This means that you might take 2 pills in one day. 2. Keep taking one pill a day until the pack is finished.
Miss 2 pills in a row	Miss 2 pills in a row
<p>First 2 Weeks:</p> <ol style="list-style-type: none"> 1. Take 2 pills the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. Use a back-up barrier method of birth control (such as a condom) if you have sex in the 7 days after you miss the pills. 	<p>First 2 Weeks:</p> <ol style="list-style-type: none"> 1. Take 2 pills the day you remember and 2 pills the next day. 2. Then take 1 pill a day until you finish the pack. 3. Use a back-up barrier method of birth control (such as a condom) if you have sex in the 7 days after you miss the pills.
<p>Third Week:</p> <ol style="list-style-type: none"> 1. Keep taking 1 pill a day until Sunday. 2. On Sunday, safely discard the rest of the pack and start a new pack that day. 3. Use a back-up barrier method of birth control (such as a condom) if you have sex in the 7 days after you miss the pills. 4. You may not have a period this month. <p>If you miss two periods in a row, you might be pregnant. Talk to your healthcare professional right away.</p>	<p>Third Week:</p> <ol style="list-style-type: none"> 1. Safely dispose of the rest of the pill pack and start a new pack that same day. 2. Use a back-up barrier method of birth control (such as a condom) if you have sex in the 7 days after you miss the pills. 3. You may not have a period this month. <p>If you miss two periods in a row, you might be pregnant. Talk to your healthcare professional right away.</p>
Miss 3 or more pills in a row	Miss 3 or more pills in a row

Sunday Start	Day 1 Start
<p>Anytime in the Cycle:</p> <ol style="list-style-type: none"> 1. Keep taking 1 pill a day until Sunday. 2. On Sunday, safely discard the rest of the pack and start a new pack that day. 3. Use a back-up barrier method of birth control (such as a condom) if you have sex in the 7 days after you miss the pills. 4. You may not have a period this month. <p>If you miss two periods in a row, you might be pregnant. Talk to your healthcare professional right away.</p>	<p>Anytime in the Cycle:</p> <ol style="list-style-type: none"> 1. Safely dispose of the rest of the pill pack and start a new pack that same day. 2. Use a back-up barrier method of birth control (such as a condom) if you have sex in the 7 days after you miss the pills. 3. You may not have a period this month. <p>If you miss two periods in a row, you might be pregnant. Talk to your healthcare professional right away.</p>

FREYA 28: If you forget any of the seven green "reminder" pills (inactive) in Week 4, just safely dispose of the pills you missed. Then keep taking one pill each day until the pack is empty. You do not need to use a back-up barrier method of birth control.

If you are not sure about the number or the colour of pills missed:

Talk to your healthcare professional right away.

Always be sure you have on hand:

- Back-up methods of birth control. These are types that do not include hormones, like latex or polyurethane condoms and spermicidal foam or gel. You will need back-up birth control if you miss pills and in some other situations. Always talk to your healthcare professional if you are not sure whether you need to use back-up birth control.
- An extra, full pack of pills.

Non-contraceptive benefits of hormonal birth control:

Several health advantages have been linked to the use of hormonal birth control:

- Reduction in the incidence of cancer of the uterus and ovaries.
- Reduction in the likelihood of developing benign (non-cancerous) breast disease and ovarian cysts.
- Less menstrual blood loss and more regular cycles. The risk of developing iron-deficiency anemia is thus reduced.
- There may be a decrease in painful menstruation and premenstrual syndrome (PMS).
- Acne, excessive hair growth and male-hormone-related disorders also may be improved.
- Ectopic (tubal) pregnancy may occur less frequently.
- Acute pelvic inflammatory disease may occur less frequently.

What are possible side effects from using FREYA?

These are not all the possible side effects you may have when taking FREYA. If you experience any side effects not listed here, tell your healthcare professional.

The following side effects may occur:

- headache
- painful menstrual cramps
- abdominal (stomach) pain
- nausea
- upper respiratory tract infections (bronchitis, runny or stuffy nose, sore throat, etc.)
- back pain
- breast tenderness
- sore throat
- diarrhea
- vomiting
- loss of strength, weakness, fatigue
- feeling of physical discomfort or uneasiness
- cough
- influenza (flu-like symptoms, fever)
- migraine, severe headaches
- dizziness
- indigestion
- urinary tract infections or inflammation
- weight gain
- difficulty wearing contact lenses
- acne
- insomnia, nervousness

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
Uncommon			
Arterial thromboembolism, myocardial infarction (blood clot in the artery, heart attack): sudden pain, discomfort, pressure, heaviness, sensation of squeezing or fullness in the shoulder, chest, arm, or below the breastbone; discomfort radiating to the back, jaw, throat, arm, stomach, feeling of being full, having indigestion or			✓

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
choking; sweating, nausea, vomiting or dizziness; extreme weakness, anxiety, or shortness of breath; rapid or irregular heartbeats			
Blood clot in the eye: sudden partial or complete loss of vision			✓
Breast lumps, breast tumour, breast cancer			✓
Deep vein thrombosis (blood clot in the leg): swelling of one leg or one foot, pain or tenderness in the leg, difficulty standing or walking, feeling of warmth in the leg, red or discolored skin on the leg, sudden pain, swelling and slight blue discoloration of an extremity			✓
Depression: persistent sad mood accompanied by difficulty sleeping, weakness, lack of energy, fatigue			✓
Edema: unusual swelling of the extremities			✓
Gallbladder disease: nausea, vomiting, pain on the upper right side of the abdomen, especially after meals, loss of appetite, fever		✓	
High blood pressure: chest pain, headaches, vision problems, nosebleeds, irregular heartbeat		✓	
Jaundice: yellowing of the skin or eyeballs, accompanied frequently by fever, fatigue, loss of appetite, dark-coloured urine			✓

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
or light-coloured bowel movements			
Liver tumour: lump in the abdomen or severe pain			✓
Pulmonary embolism (blood clot in the lung): coughing blood, sharp pain in chest, or sudden shortness of breath			✓
Stroke: sudden severe headache or vomiting, dizziness or fainting, disturbances of vision or speech, weakness or numbness in an arm or leg			✓
Vaginal bleeding changes: increased or decreased menstrual bleeding, spotting or bleeding between periods, infrequent periods or absence of bleeding	✓		
Vaginal infection: itching or unusual or increased vaginal discharge	✓		
Unknown Frequency			
Allergic reaction (hypersensitivity, angioedema): rash or hives, swelling of the face, lips, tongue and/or throat, difficulty in breathing or swallowing, feeling sick to your stomach and throwing up			✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store between 15-30°C. Keep in a safe place out of the reach of children and pets.

If you want more information about FREYA:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website www.mylan.ca, or by calling 1-844-596-9526.

This leaflet was prepared by Mylan Pharmaceuticals ULC.

Last Revised: AUG 01, 2023